pantoprazole profile

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4679
CHEMBL ID	1502
CHEBI ID	7915
SCHEMBL ID	29465
MeSH ID	M0177102

Synonym
BIDD:GT0003
AB01275513-01
BRD-A22380646-001-01-5
pantozol
5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1h-benzimidazole
pantoprazole (usan/inn)
D05353
skf-96022
hsdb 7292
by 1023
5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole
pantoprazolum [inn-latin]
sk&f-96022
pantoprazol [inn-spanish]
by-1023
1h-benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-
sk&f 96022
BSPBIO_002320
pantoprazolum
pantoprazol
CHEBI:7915 ,
pantoprazole
102625-70-7
DB00213
NCGC00095188-01
NCGC00095188-02
SPECTRUM1505818
NCGC00095188-03
AC-679
HMS2090H03
HMS2093F14
5-difluoromethoxy-2-(3,4-dimethoxy-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole
6-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole
5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole
bdbm50241342
zovanta
sk-96022
nsc-759257
altopan
CHEMBL1502 ,
HMS1922H20
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole
A800593
6-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazole
tox21_111477
cas-102625-70-7
dtxcid803416
dtxsid4023416 ,
nsc759257
pharmakon1600-01505818
apo-pantoprazole
2-(((3,4-dimethoxy-2-pyridinyl)methyl)-sulfinyl)-5-methyl-1h-1,3-benzimidazole
pantecta control
pantoprazole [usan:inn:ban]
nsc 759257
ec 600-331-6
panyocid
d8tst4o562 ,
unii-d8tst4o562
smr002533625
MLS003882559
FT-0602547
NCGC00095188-04
AKOS015894910
S2105
gtpl7260
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1h-1,3-benzodiazole
(+/-)-pantoprazole
pantoprazole [mi]
5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole
pantoprazole [who-dd]
6-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
pantoprazole [ema epar]
154644-14-1
5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
pantoprazole [mart.]
1h-benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)-
2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-5-difluoromethoxy-1h-benzimidazole
by1023
pantoprazole [hsdb]
pantoprazole [usan]
pantoprazole [inn]
pantoprazole [vandf]
CCG-213558
CS-3161
HY-17507
SCHEMBL29465
NCGC00095188-05
tox21_111477_1
5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazole
5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazole
AB01275513_02
STL451032
6-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methane]sulfinyl}-1h-1,3-benzodiazole
J-000744
sr-01000763715
SR-01000763715-3
SBI-0206873.P001
142706-18-1
(r)-pantoprazole
pantoprazole-d3
BCP21400
Q286846
pantoprazole (protonix)
5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)
skf96022
AKOS034831879
BRD-A22380646-001-02-3
(r)-(+)-pantoprazole;(+)-(r)-pantoprazole;pantoprazole isomer(r) impurity
BCP20279
SB17368
BS-14224
CCG-268437
(r)-(+)-pantoprazole;r-enantiomer of pantoprazole;(r)-pantoprazole;5-(difluoromethoxy)-2-[(r)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole ;5-(difluoromethoxy)-2-[(r)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole. - see mo
A901011
5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole
NCGC00389443-01
(+)-(r)-pantoprazole
EN300-19767202
P2262
(r)-6-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
(s)-6-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
(s)-pantoprazole
pantoprazol (inn-spanish)
pantoprazolum (inn-latin)
a02bc02
pantoprazole (mart.)
5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzimidazole
5-(difluoromethoxy)-2-

Excerpt	Reference	Relevance
"Pantoprazole is a proton pump inhibitor mainly used to treat conditions causing excess stomach acid. "	( Pantoprazole-induced Stevens-Johnson Syndrome: A Case-report. Bouattour, E; Charfi, O; Daldoul, M; El Aidli, S; Fenniche, S; Hammami-Ghorbe, H; Lakhoua, G; Zaiem, A, 2024)	4.33
"Pantoprazole is a Proton Pump Inhibitor, commonly used by clinicians all over the world as a gastric acid synthesis inhibitor for a wide variety of gastrointestinal disorders. "	( Anaphylaxis to Pantoprazole: A Case Report and Prerequisite for Vigilant Prescribing Practises for Proton Pump Inhibitors. Begum, A; Fayaz, SH; James, J; Rani, J; Sathyanarayanan, V, 2022)	2.52
"Pantoprazole is a proton pump inhibitor that has been shown to inhibit bone resorption. "	( Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice. Brüel, A; Thomsen, JS; Vegger, JB, 2017)	3.34
"Pantoprazole is a frequently prescribed proton pump inhibitor (PPI) commonly utilized in the management of gastrointestinal symptoms. "	( Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine. Avella, S; Barceló, B; Dastis, M; Gomila, I; Rosell, A; Sahuquillo, L, 2017)	2.22
"Pantoprazole magnesium is a safe, effective, and well-tolerated drug that significantly improves GERD symptoms."	( Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014)	2.12
"Pantoprazole is a proton pump inhibitor drug mainly used for treating peptic diseases. "	( Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples. Braun, T; Frechen, S; Fuhr, U; Holzgrabe, U; Hüttner, S; Kinzig, M; Schröter, M; Sigaroudi, A; Sörgel, F; Stelzer, C, 2016)	2.24
"Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4. "	( Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Altinbas, A; Babaoglu, MO; Bozkurt, A; Goktas, MT; Kalkisim, S; Karaca, RO; Kilincalp, S; Yasar, U; Yuksel, I, 2017)	2.12
"Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment. "	( Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016)	2.1
"Pantoprazole is a proton pump inhibitor prodrug used in the treatment of gastric ulcers and gastroesophageal disease. "	( Development and in vitro evaluation of pantoprazole-loaded microspheres. Basci, N; Comoglu, T; Dogan, A; Gonul, N, 2008)	2.06
"Pantoprazole is a weak base (pka approximately equal to 4) with its stability in aqueous solution dependent on pH. "	( [Stability of pantoprazole in parenteral nutrition units]. Gómez-Maldonado, J; González Muñiz, V; Muñoz Castillo, I; Valverde Molina, E, )	1.93
"Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. "	( Pantoprazole: a proton pump inhibitor. Moreira Dias, L, 2009)	3.24
"Pantoprazole is an irreversible inhibitor of H(+) /K(+) adenosine triphosphatase proton pump. "	( Toxicology and toxicokinetics of oral pantoprazole in neonatal and juvenile dogs. Cappon, GD; Hurtt, ME; Mansell, P; Minck, D; Robinson, K, 2011)	2.08
"Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease."	( Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Bochenek, W; DeVault, K; Kovacs, TO; Miska, D; Wilcox, CM, 2002)	2.05
"Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion. "	( Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003)	3.2
"Pantoprazole is a proton-pump inhibitor (PPI) that is commonly prescribed for the treatment of gastroesophageal reflux-related disorders. "	( Pantoprazole-induced acute interstitial nephritis. Ahmed, S; Moore, I; Nayar, A; Sayer, JA; Tapson, JS, )	3.02
"Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically. "	( Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. Cao, H; Hu, ZQ; Ikejima, T; Sun, LX; Wang, MW; Zhao, WH, 2005)	2.06
"Pantoprazole is an important drug in the treatment of acid-related disorders. "	( Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. Colomé, LM; Guterres, SS; Pohlmann, AR; Raffin, RP, 2006)	2.01
"Pantoprazole is a prodrug used in the treatment of acid related disorders and Helicobacter pylori infections. "	( Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: effect of the scale of production and process validation. Guterres, SS; Jornada, DS; Pohlmann, AR; Raffin, RP; Ré, MI, 2006)	2.23
"Pantoprazole sodium is a proton pump inhibitor, used in acid-related disorders, like peptic ulcers and gastroesophageal reflux. "	( Increasing sodium pantoprazole photostability by microencapsulation: effect of the polymer and the preparation technique. Colomé, LM; Guterres, SS; Pohlmann, AR; Raffin, RP; Schapoval, EE, 2008)	2.12
"Pantoprazole is a new substituted benzimidazole that inhibits the parietal cell H+,K(+)-adenosine triphosphatase."	( Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Classen, M; Schepp, W, 1995)	3.18
"Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K(+)-ATPase."	( A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Herz, R; Hölscher, AH; Mössner, J; Schneider, A, 1995)	2.04
"Pantoprazole is a newly developed gastric H+/K(+)-adenosine triphosphatase inhibitor with a potent and long-acting inhibitory effect on gastric acid secretion."	( Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Hotz, J; Plein, K; Rose, K; Schönekäs, H, 1995)	3.18
"Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K(+)-ATPase."	( Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Gütz, H; Hüttemann, W; Schepp, W; Witzel, L, 1995)	3.18
"Pantoprazole is a new substituted benzimidazole, which is a potent inhibitor of gastric acid secretion by its inhibition of H+,K(+)-ATPase. "	( A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. Cremer, M; Delle Fave, G; Lambert, R; Lamers, CB; Maier, C, 1995)	2.04
"Pantoprazole is a new substituted benzimidazole that blocks the H+/K(+)-ATPase in the gastric mucosa and thus inhibits acid secretion."	( Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. Judmaier, G; Koelz, HR, 1994)	2.09
"Pantoprazole is a specific inhibitor of the H+/K(+)-ATPase of the gastric parietal cell. "	( Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Wurst, W, 1994)	1.96
"Pantoprazole is a pyridinyl-2-methylenesulfinyl-2-benzimidazole derivative. "	( The site of action of pantoprazole in the gastric H+/K(+)-ATPase. Besancon, M; Sachs, G; Shin, JM; Simon, A, 1993)	2.04
"Pantoprazole was shown to be a highly-effective and well-tolerated treatment for acute duodenal ulcer. "	( Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. Rehner, M; Rohner, HG; Schepp, W, 1995)	2.09
"Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzyme system in man. "	( Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Bliesath, H; Hartmann, M; Huber, R; Lücker, PW; Lühmann, R; Theiss, U; Wurst, W, 1996)	1.94
"Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+-ATPase."	( Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Bethke, TD; Botha, JF; Cariem, AK; Eloff, FP; Grundling, HD; Honiball, PJ; Marks, IN; Segal, I; Simjee, AE; Spies, SK; Theron, I; van Rensburg, CJ; van Zyl, JH, 1996)	2.03
"Pantoprazole is a specific inhibitor of the H+/K(+)-ATPase of the gastric parietal cell. "	( Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Wurst, W, 1996)	1.97
"Pantoprazole is a new substituted benzimidazole which inhibits gastric H+,K(+)-ATPase."	( Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Belaïche, J; Colin, R; Corinaldesi, R; Geldof, H; Maier, C; Valentini, M, 1995)	3.18
"Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion. "	( Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Fitton, A; Wiseman, L, 1996)	3.18
"Pantoprazole is a selective proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzymes in man. "	( Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Birkel, M; Bliesath, H; Ehrlich, A; Fuder, H; Hartmann, M; Huber, R; Lücker, PW; Steinijans, VW; Timmer, W; Wieckhorst, G; Wurst, W, 1996)	1.98
"Pantoprazole (PAN) is a proton pump inhibitor that is administered as a racemic mixture. "	( Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study. Hakusui, H; Nakamichi, N; Sekino, H; Tanaka, M; Yamazaki, H, 1997)	1.99
"Pantoprazole is a new Proton Pump Inhibitor that has demonstrated to be superior to ranitidine in the healing of the acid related diseases."	( [Superiority of pantoprazole over ranitidine in the treatment of duodenal ulcer. Mexican clinical experience. Mexican Study Group of Pantoprazole++ in Duodenal Ulcer]. Dibildox, M; Fischer, R; Gallo, S; Rose, K; Tomás-Pons, J, )	1.92
"Pantoprazole is a selective inhibitor of the gastric H+/K+-ATPase with a low potential to interact with the cytochrome P450 enzyme system. "	( Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Bahlmann, J; Hartmann, M; Huber, R; Kliem, V; Lühmann, R; Wurst, W, 1998)	2.07
"Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+. "	( One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997)	2
"Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 system, and linear pharmacokinetics. "	( Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Ehrlich, A; Emeklibas, S; Fuder, H; Hartmann, M; Lücker, PW; Lühmann, R; Timmer, W; Wurst, W, 1998)	1.97
"Pantoprazole is a H+/K+-ATPase inhibitor with a minimized potential of interaction with the cytochrome P450 system. "	( Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Bliesath, H; Hartmann, M; Huber, R; Koch, H; Mascher, H; Steinijans, VW; Wurst, W, 1998)	3.19
"Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion."	( Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999)	2.06
"Pantoprazole is a proton pump inhibitor which has recently had its clinical license extended to include maintenance therapy for the treatment of reflux oesophagitis, Helicobacter pylori eradication and short-term intravenous administration. "	( Pantoprazole, Prout and the proton pump. Modlin, I; Playford, RJ; Podas, T, 1999)	3.19
"Pantoprazole seems to be a safe drug in combination with CyA."	( Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients. Lorf, T; Ramadori, G; Ringe, B; Schwörer, H, 2000)	3.19
"Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile. "	( Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Horvat, D; Ivandić, A; Jurisić-Orzen, D; Kotromanović, Z; Maksimović, Z; Males, J; Mandić, B; Nedić, P; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A; Vladika, I; Vranjes, Z, 1999)	3.19
"Pantoprazole is a new proton pump inhibitor indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) and is available in both oral and intravenous (IV) formulations."	( Clinical experience with pantoprazole in gastroesophageal reflux disease. Avner, DL, 2000)	2.05
"Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K(+)-ATPase) inhibitor."	( Pantoprazole. Poole, P, 2001)	2.47
"Pantoprazole is a proton pump inhibitor that has demonstrated high clinical efficacy."	( Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Bochenek, W; Castell, DO; Katz, PO; Tutuian, R, 2002)	1.3
"Pantoprazole is a newly developed benzimidazole derivative with strong inhibitory actions on gastric acid secretion by blocking H(+)-K(+)-ATPase. "	( Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Khalil, H; Leucht, U; Lühmann, R; Müller, P; Schneider, A; Simon, B, 1992)	1.97

Excerpt	Reference	Relevance
"Pantoprazole has an excellent safety profile and a low potential for drug-drug interactions."	( Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Devault, KR, 2007)	2.5
"Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments."	( Pantoprazole: a proton pump inhibitor. Moreira Dias, L, 2009)	2.52
"Pantoprazole has an excellent safety record and shows only minor interaction with other drugs."	( Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. Beglinger, C; Lehmann, FS, 2005)	1.48
"Pantoprazole has been shown to exert a negative inotropic effect in isolated myocardium. "	( Negative hemodynamic effects of pantoprazole at high infusion rates in mice. Didié, M; Hasenfuß, G; Jacobshagen, C; Schillinger, W; Seidler, T; Sossalla, S; Teucher, N; Unsöld, B, 2015)	2.14
"Pantoprazole has indications in gastroesophageal reflux disease and peptic ulcer disease, along with indications as co-therapy in the eradication of Helicobacter pylori infection and in the control of the acid secretion associated with the Zollinger-Ellison syndrome, as well as in NSAID ulcer prevention."	( Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Devault, KR, 2007)	2.5
"Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments."	( Pantoprazole: a proton pump inhibitor. Moreira Dias, L, 2009)	2.52
"Pantoprazole has pharmacokinetic properties that document a longer half-life compared with the other proton-pump inhibitors, and pantoprazole has the slowest inhibition recovery rate."	( Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Orr, WC, 2005)	1.05
"Pantoprazole has an excellent safety record and shows only minor interaction with other drugs."	( Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. Beglinger, C; Lehmann, FS, 2005)	1.48
"Pantoprazole has been assessed in most of the clinical situations where acid suppression is required, and showed great efficacy and an excellent safety profile."	( Pantoprazole: from drug metabolism to clinical relevance. Bardou, M; Martin, J, 2008)	2.51
"Pantoprazole has been shown to be as effective as omeprazole in the treatment of reflux oesophagitis."	( Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Belaïche, J; Colin, R; Corinaldesi, R; Geldof, H; Maier, C; Valentini, M, 1995)	3.18
"pantoprazole has lower CYP1A induction potential than omeprazole and lansoprazole."	( An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors. Masubuchi, N; Okazaki, O, 1997)	1.27
"Pantoprazole has been shown to be more effective than ranitidine (P < 0.05), famotidine (P < 0.001), and nizatidine (P < 0.05), and at least as effective as omeprazole, in healing erosive esophagitis and relieving associated symptoms of GERD, including regurgitation."	( Clinical experience with pantoprazole in gastroesophageal reflux disease. Avner, DL, 2000)	1.33
"Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa."	( Pantoprazole: a new proton pump inhibitor. Jungnickel, PW, 2000)	2.47
"Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans."	( Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. Ferron, GM; Mayer, PR; McKeand, W, 2001)	1.33
"Pantoprazole has been evaluated in more than 100 clinical trials involving more than 11,000 patients."	( Pantoprazole. Poole, P, 2001)	2.47

Excerpt	Reference	Relevance
"Pantoprazole prevented the increase in acute kidney injury biomarkers in cisplatin-treated patients."	( Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial. El-Haggar, S; Ghonaim, E; Gohar, S, 2021)	1.63
"pantoprazole has lower CYP1A induction potential than omeprazole and lansoprazole."	( An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors. Masubuchi, N; Okazaki, O, 1997)	1.27

Excerpt	Reference	Relevance
"Pantoprazole pretreatment aggravate these arrhythmias and increased mortality."	( Chronic pantoprazole administration and ischemia--reperfusion arrhythmias in vivo in rats--antiarrhythmic or arrhythmogenic? Abdel-Kawy, HS, 2015)	1.57
"In pantoprazole-treated rats a decreased BMD was detected (0.2618±0.0133g/cm(2)vs. "	( Effects of long-term administration of pantoprazole on bone mineral density in young male rats. Bolanowski, M; Jędrzejuk, D; Kwiatkowska, J; Landwójtowicz, M; Matuszewska, A; Nowak, B; Pieśniewska, M; Rzeszutko, M; Szandruk, M; Szeląg, A; Zduniak, K, 2016)	1.32
"In pantoprazole-treated animals biomechanical analysis revealed a significantly reduced bending stiffness at 5 weeks after fracture compared to controls."	( Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Garcia, P; Histing, T; Holstein, JH; Klein, M; Menger, MD; Metzger, W; Pohlemann, T; Scheuer, C; Stenger, D, 2012)	2.34
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI."	( Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012)	2.21
"Pantoprazole pretreatment reduced the TSF response and blood ethanol concentrations implicating mechanisms induced by gastric mucosal damage."	( Sphincter of Oddi function in the Australian brush-tailed possum is inhibited by intragastric ethanol. Carati, CJ; Kawamoto, M; Saccone, GT; Schloithe, AC; Sonoda, Y; Toouli, J; Woods, CN, 2007)	1.06
"pantoprazole treatment were compared with those at the end of the i.v."	( Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000)	1.3
"Treatment with pantoprazole did not have any bone protective or deleterious effects."	( Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice. Brüel, A; Thomsen, JS; Vegger, JB, 2017)	2.24
"Pretreatment with pantoprazole increased tissue penetration of doxorubicin in MCCs."	( Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Lee, C; Patel, KJ; Tan, Q; Tannock, IF, 2013)	0.99
"Treatment with pantoprazole and aprepitant significantly inhibited the gastric secretion, total acidity, and esophagitis index."	( Effect of monotherapy and combination therapy of pantoprazole and aprepitant in gastric esophageal reflux disease in albino rats. Kaithwas, G; Kumar, A; Kumar, M; Raj, P; Shukla, K, 2014)	1
"Treatment with pantoprazole reduced the frequency and severity of gastroesophagopharyngeal acid reflux in patients with chronic pharyngitis and laryngitis."	( Effect of pantoprazole in patients with chronic laryngitis and pharyngitis related to gastroesophageal reflux disease: clinical, proximal, and distal pH monitoring results. Ben Mustapha, N; Besbes, G; Bibani, N; Boubaker, J; Filali, A; Kallel, L; Karoui, S; Matri, S; Sahtout, S; Serghini, M; Zouiten, L, 2010)	1.1
"Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life."	( [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease]. Gillessen, A, 2010)	1
"Treatment with pantoprazole resulted in a significant reduction of acidic reflux in both PPI responders and PPI nonresponders."	( Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Ellenrieder, V; Gress, TM; Kunsch, S; Linhart, T; Neesse, A; Nell, C, 2012)	0.72
"Treatment with pantoprazole did not have influence on the clinical course of acute pancreatitis. "	( [Effect of proton pump inhibitor in patients with acute pancreatitis - pilot study]. Hong, SP; Kim, WH; Ko, KH; Kwon, CI; Park, PW; Yoo, JH; Yoo, KH; Yoon, H, 2012)	0.73
"Treatment with pantoprazole resulted in significantly faster first-time relief from daytime and night-time GERD-related symptoms than esomeprazole. "	( Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Gatz, G; Hole, U; Scholten, T, 2003)	1.06
"Treatment with pantoprazole (80 mg/day) determines their improvement and complete regression."	( Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005)	0.91
"Treatment with pantoprazole 20 mg once daily or esomeprazole 20 mg once daily provides similarly effective and well-tolerated maintenance of previously healed gastroesophageal reflux disease irrespective of baseline H. "	( Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007)	1.07
"Pretreatment with pantoprazole suppresses H. "	( Pantoprazole suppresses Helicobacter pylori without affecting cure. Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999)	2.08
"Treatment with pantoprazole led to a significant increase in serum gastrin concentration and GPC density in all strains."	( Ultrastructural investigations of the enterochromaffin-like (ECL) cells in three different rat strains (Sprague-Dawley, Fischer 344, Wistar) after treatment with the H+,K(+)-ATPase inhibitor pantoprazole. Ockert, D; Reznik, GK; Rohr, I, 1992)	0.81

Excerpt	Reference	Relevance
" Minor adverse events include headache, diarrhoea, dizziness, pruritus and rash."	( Safety of proton pump inhibitors--an overview. Arnold, R, 1994)	0.29
" Fifty-four (24%) patients experienced adverse events; 15 of these withdrew."	( One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997)	0.56
" For patients, temporarily unable to take oral medications, this regimen offers safe and reliable gastric acid suppression and allows the possibility of changing between the oral and intravenous administration without the need for dose adjustment."	( Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Bethke, T; Fischer, R; Luhmann, R; Riesenhuber, C; Schutze, K; Wurzer, H, )	0.44
"Of the 178 adverse events, experienced by 88 (56%) patients (intention-to-treat population), 12 (7%) were assessed by the investigators as possibly related to the study medication."	( Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999)	0.61
"Pantoprazole 40 mg proved to be safe and efficacious during a 2-year prophylaxis treatment in patients with healed reflux oesophagitis."	( Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999)	2.06
"To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England."	( The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Dunn, NR; Freemantle, S; Martin, RM; Shakir, S, 2000)	0.51
" We performed serial endoscopy, checked for adverse events, and laboratory values."	( Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001)	1.75
" Treatment was safe; only four patients had adverse events definitely related to pantoprazole."	( Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001)	1.98
" We conclude that the use of intravenous P allows a safe and efficient control of the acid ipersecretion in patients with ZES."	( [Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma]. Modlin, IM, )	0.38
" Pantoprazole was safe and well tolerated."	( Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. Delgado, J; Dibildox, M; Gonzalez, J; Madrazo-de la Garza, A; Vargas, A; Yañez, P, 2003)	1.52
"To estimate the frequency of adverse events and drug interactions reported to the Food and Drug Administration in patients receiving omeprazole, lansoprazole or pantoprazole."	( A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003)	0.72
"The study involved a search of the Food and Drug Administration's database for adverse events and drug interactions with omeprazole, lansoprazole or pantoprazole as primary or secondary suspect drug."	( A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003)	0.72
" Safety evaluations included adverse events and laboratory assessments."	( Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004)	0.63
"3%) and there were no serious adverse events."	( The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004)	0.59
" Only four patients had adverse events considered to be definitely related to pantoprazole."	( Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005)	2
" In the present article, the adverse effects of PPIs are reviewed, with special emphasis on those related to their continued administration and on the special circumstances of patients, as in the case of the elderly, those with liver failure, pregnant and breastfeeding mothers and children."	( [Safety of proton pump inhibitors]. Esplugues, JV; Martí-Cabrera, M; Ponce, J, 2006)	0.33
" A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events."	( Long-term proton pump inhibitor use in children: a retrospective review of safety. Boyer, K; Tolia, V, 2008)	0.35
" It is safe to give pantoprazole intravenously and continuously for treatment of severe erosive esophagitis."	( A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Barrie, M; Cai, Q; Olejeme, H; Rosenberg, MD, 2008)	0.9
" Adverse events did not significantly differ between pantoprazole and placebo."	( Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Berghöfer, P; Dattani, ID; Enns, R; Fischer, R; Gonzalez Carro, P; Maritz, JF; Schwan, T; van Rensburg, C, 2008)	0.91
" No between-group differences in adverse event frequency were noted."	( Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. Comer, GM; Hinz, M; Kierkus, J; Kum-Nji, P; Li, H; Maguire, MK; Mahomedy, SH; Winter, H, 2010)	0.67
" There was no evidence of accumulation with multiple dosing or reports of serious drug-associated adverse events."	( A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. Bishop, P; Comer, GM; James, LP; Katz, MH; Kearns, GL; Maguire, MK; Meng, X; O'Gorman, MA; Rath, N; Tammara, B; Ward, RM, 2011)	0.6
" Both treatments were well tolerated; most adverse events were of mild or moderate severity and unrelated to the study medication, and there were no unexpected safety concerns."	( Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial. Hein, J, 2011)	0.64
" The number of patients that experienced any adverse events was 175/5,027 (3."	( Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014)	0.67
" Better holistic insights into glucocorticoid-induced changes are crucial for effective use as concurrent medication and management of adverse effects."	( Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects. Albrecht, V; Bordag, N; Jürchott, K; Klie, S; Schichor, C; Schiewe, H; Schwartz, C; Selbig, J; Tonn, JC; Vierheller, J, 2015)	0.42
"In our best knowledge, our case was the first case in this regard and that points the possibility of all cross-reactive pattern in patients with pantoprazole anaphylaxis and the importance of a thorough drug allergy work-up for finding safe alternatives."	( A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative. Bavbek, S; Kendirlinan, R; Sozener, ZC; Turedi, O, 2017)	1.06
" Safety was evaluated on the basis of adverse events, vital signs, laboratory tests, and physical examination."	( Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. Chen, J; Jiao, HW; Li, YQ; Meng, L; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Yu, L; Yu, LY; Yuan, ZQ; Zhang, HW; Zhang, XH, 2018)	0.73
"All adverse events were mild and of limited duration."	( Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. Chen, J; Jiao, HW; Li, YQ; Meng, L; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Yu, L; Yu, LY; Yuan, ZQ; Zhang, HW; Zhang, XH, 2018)	0.73
" The most common adverse events in the pooled group were abdominal discomfort, abdominal distention, dyspepsia, and nausea, but none of these was deemed to be clinically meaningful."	( Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, C; Macêdo, EA; Pott Júnior, H; Scheinberg, M, 2018)	0.72
" These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies."	( Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)	0.51
"In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections."	( Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)	0.75
" Adverse drug effects were found in 36 patients from the twice a day group and 50 patients from the four times a day group (P = ."	( Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Kim, JH; Kim, JY; Lee, SY; Park, HS; Sung, IK, 2020)	0.56
"5 g/d of metronidazole, and 600 mg/d of bismuth subcitrate for one week is effective and safe as the conventional four times a day therapy."	( Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Kim, JH; Kim, JY; Lee, SY; Park, HS; Sung, IK, 2020)	0.56
"The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs)."	( Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database. Eswaran, M; Kulkarni, AR; Nair, HP; Subeesh, V, 2023)	2.59
" As a result, further clinical surveillance is needed to quantify and validate potential hazards associated with pantoprazole-related adverse events."	( Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database. Eswaran, M; Kulkarni, AR; Nair, HP; Subeesh, V, 2023)	2.56
" •Drug adverse effects were fewer and milder in the gemifloxacin group."	( EFFICACY AND SAFETY OF GEMIFLOXACIN CONTAINING TREATMENT REGIMEN IN FIRST-LINE TREATMENT OF HELICOBACTER PYLORI. Alanli, R; Aydin, MF; Ergül, B; Kucukay, MB; Yakaryilmaz, F, )	0.13

Excerpt	Reference	Relevance
" The range of clinically acceptable variation in the pharmacokinetic characteristics of drug A defines the equivalence range."	( Lack of pharmacokinetic interaction as an equivalence problem. Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW, 1991)	0.28
" A good dose linearity was observed for AUC (0, infinity) and Cmax over the dose range from 5 to 80 mg."	( Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Müller, P; Simon, B; Wurst, W, 1990)	0.28
" AUC, Cmax and t1/2 of the drug after repeated oral intake were not significantly different when compared with a single dose at either 20 mg or 40 mg."	( Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Hartmann, R; Huber, R; Lühmann, R; Marinis, E; Müller, P; Simon, B; Wurst, W, 1990)	0.28
" Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively."	( Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Bliesath, H; Bohnenkamp, W; Hartmann, M; Huber, R; Lühmann, R; Müller, P; Simon, B; Wurst, W, 1990)	0.74
" If two drugs of the same class have a similar dose-efficacy profile, then the favourable/unfavourable balance of the pharmacokinetic characteristics of the drugs may determine the drug of choice."	( Pharmacokinetics--a relevant factor for the choice of a drug? Benet, LZ; Zech, K, 1994)	0.29
" The dose-dependency of a range of pantoprazole pharmacokinetic characteristics was studied."	( Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Wurst, W, 1994)	0.8
" The dose-dependency of a range of pantoprazole pharmacokinetic characteristics was studied."	( Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Wurst, W, 1996)	0.8
" The range of clinically acceptable variation in the pharmacokinetic characteristics of drug A defines the equivalence range."	( Lack of pharmacokinetic interaction as an equivalence problem. Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW, 1996)	0.29
" Lack of pharmacokinetic interaction was handled as an equivalence problem."	( Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath, H; Huber, R; Koch, HJ; Mascher, H; Steinijans, VW; Wurst, W, 1996)	0.56
" Lack of pharmacokinetic interaction was handled as an equivalence problem."	( Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath, H; Huber, R; Koch, HJ; Mascher, H; Steinijans, VW; Wurst, W, 1996)	0.56
"021 1 h-1 kg-1 for test and reference) and elimination half-life (36."	( Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Bliesath, H; Brod, I; Gugler, R; Hartmann, M; Huber, R; Klotz, U; Rudi, J; Steinijans, VW; Wurst, W, 1996)	0.56
" The primary pharmacokinetic characteristics for extent and rate of absorption were AUC(0-24h) and % PTF, respectively."	( Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Bliesath, H; Hartmann, M; Huber, R; Koch, HJ; Mascher, H; Steinijans, VW; Wurst, W, 1996)	1.74
" As a pharmacodynamic parameter, the prothrombin time ratio was determined on days 9 and 10 (reference value) and on days 14 and 15 (test value), and the ratio test/reference was evaluated according to equivalence criteria."	( Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Birkel, M; Bliesath, H; Ehrlich, A; Fuder, H; Hartmann, M; Huber, R; Lücker, PW; Steinijans, VW; Timmer, W; Wieckhorst, G; Wurst, W, 1996)	0.53
" The pharmacokinetic characteristics AUC0-24h and Cmax of S(-)- and R(+)-phenprocoumon were also investigated using equivalence criteria."	( Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Birkel, M; Bliesath, H; Ehrlich, A; Fuder, H; Hartmann, M; Huber, R; Lücker, PW; Steinijans, VW; Timmer, W; Wieckhorst, G; Wurst, W, 1996)	0.53
"Pantoprazole does not interact with the anticoagulant phenprocoumon on a pharmacodynamic or pharmacokinetic level."	( Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Birkel, M; Bliesath, H; Ehrlich, A; Fuder, H; Hartmann, M; Huber, R; Lücker, PW; Steinijans, VW; Timmer, W; Wieckhorst, G; Wurst, W, 1996)	1.98
" The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs."	( Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Berstad, A; Hatlebakk, JG, 1996)	0.29
"Haemodialysis has no influence on the pharmacokinetic characteristics of pantoprazole."	( Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Bahlmann, J; Hartmann, M; Huber, R; Kliem, V; Lühmann, R; Wurst, W, 1998)	0.86
" For pantoprazole, no differences were observed in AUC and Cmax after single and repeated dosing."	( Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Ehrlich, A; Huber, R; Lücker, PW; Mascher, H; Sander, P; Wiedemann, A, )	0.89
" As increased cisapride concentrations may result in longer electrocardiogram (ECG) QTc intervals, a crossover study was conducted in healthy subjects to evaluate the oral pharmacokinetic interaction between cisapride (20 mg) and pantoprazole (40 mg)."	( Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. Ferron, GM; Fruncillo, RJ; Martin, PT; Mayer, PR; Paul, JC; Yacoub, L, 1999)	0.74
"To study the potential pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline at steady state."	( Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline. Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y, 2000)	0.78
"No significant changes in the steady-state theophylline maximum plasma concentration (Cmax), time to Cmax (Tmax), minimum plasma concentration (Cmin), area under the plasma concentration-time curve over the 12-h dosing interval (AUC0-12), or apparent total oral clearance (CL/F) were observed within the two treatment groups when theophylline was administered alone or in combination with lansoprazole or pantoprazole."	( Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline. Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y, 2000)	0.71
" An irreversible pharmacodynamic response model was successfully developed and validated."	( Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. Ferron, GM; Mayer, PR; McKeand, W, 2001)	0.6
" To determine the role of cytochrome P450 (CYP) 2C19 in the stereoselective metabolism of pantoprazole, we investigated the pharmacokinetic disposition of (+)- and (-)-pantoprazole in 7 extensive metabolizers and 7 poor metabolizers of S-mephenytoin."	( Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Ishizaki, T; Kaneko, S; Ohkubo, T; Otani, K; Ryokawa, Y; Sugawara, K; Suzuki, A; Tanaka, M, 2001)	0.81
"This study sought to determine whether dosage adjustment of pantoprazole is required in patients with moderate or severe hepatic impairment by comparing the pharmacokinetic profile of pantoprazole in such patients with that in healthy slow metabolizers of pantoprazole, in whom no dosage adjustment is required."	( Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001)	0.88
" Pharmacokinetic data were compared between the 2 groups with hepatic impairment and against historical data from 17 healthy subjects who were genetically slow CYP2C19 metabolizers of pantoprazole."	( Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001)	0.83
" Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal."	( The clinical importance of proton pump inhibitor pharmacokinetics. Thomson, AB; Yacyshyn, BR, 2002)	0.31
" For pantoprazole, Cmax and AUC were unchanged on day 7 vs day 1, confirming its high and constant bioavailability."	( Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Gatz, G; Huber, R; Mascher, H; Müller, P; Pascu, O; Sander, P; Simon, B, 2003)	1.08
" For esomeprazole, the Cmax and AUC increased after multiple dosing; for pantoprazole the pharmacokinetics were predictable and independent of the number of administered doses."	( Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Gatz, G; Huber, R; Mascher, H; Müller, P; Pascu, O; Sander, P; Simon, B, 2003)	0.8
" Because of the apparent safety of PPIs and a well-demonstrated dose-response-effect relationship in adults, pediatric pharmacokinetic data and an exposure correlate, such as the dose-area-under-the-plasma-concentration-versus-time-curve relationship, can be used as a bridge to determine pediatric dosing."	( Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. Kearns, GL; Winter, HS, )	0.13
" The pharmacokinetic parameters of omeprazole and pantoprazole were compared to those after intake of both agents alone."	( Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Calabresi, L; Di Paolo, A; Ferrara, S; Pazzucconi, F; Sirtori, C; Tacca, MD, 2004)	0.83
" These pharmacokinetic characteristics confirm the suitability of this oral solid dosage form for use in future clinical trials."	( Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R, 2005)	0.33
" Intragastric pH was recorded for 24 h after drug administration for pharmacodynamic evaluation."	( Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals. Giguère, S; Ryan, CA; Sanchez, LC; Vickroy, T, 2005)	0.59
" The pharmacokinetic differences between pantoprazole enantiomers were evaluated by the experiments of the in situ perfusion into rat small intestine, the protein binding, and the in vitro metabolism in rat liver microsomes of pantoprazole enantiomers."	( Pharmacokinetic differences between pantoprazole enantiomers in rats. Xie, Z; Xu, H; Zhang, Y; Zhong, D, 2005)	0.87
" Speed and duration of acid suppression and intensity of effect after a single dose may be important pharmacodynamic properties in clinical use."	( Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007)	0.58
"To demonstrate the pharmacodynamic comparability between oral 40 mg pantoprazole delayed-release granules and tablets."	( Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007)	1.09
"To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual variability of dabigatran pharmacokinetics in order to assess possible gender differences; and to assess the effect of pantoprazole coadministration on the bioavailability of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.52
"The primary pharmacokinetic measurements included the area under the plasma concentration-time curve at steady state (AUC(ss)), maximum (C(max,ss)) and minimum (C(min,ss)) plasma concentrations at steady state, terminal half-life (t((1/2))), time to reach C(max,ss) and renal clearance of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.35
" Intra- and interindividual pharmacokinetic variability in the overall population was low (<30% coefficient of variation), indicating that dabigatran has a predictable pharmacokinetic profile."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.35
"Dabigatran demonstrated reproducible and predictable pharmacokinetic and pharmacodynamic characteristics, together with a good safety profile, when administered to healthy elderly subjects."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.35
" The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding."	( Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Stangier, J, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Pharmacokinetic values were similar in patients from ages 2 to 16 years and to those previously obtained in adults."	( Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. Adcock, KG; Blumer, J; Daniel, JF; Gaedigk, A; James, LP; Kearns, GL; Paul, J; Reed, MD; Schexnayder, S, 2008)	0.6
"Our population approach has determined the pharmacokinetic parameters of intravenous pantoprazole in paediatric intensive care patients and the relative importance of factors influencing its disposition."	( Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Faure, C; Labbé, L; Litalien, C; Mouksassi, MS; Nguyen, B; Pettersen, G; Théorêt, Y, 2009)	0.84
"73 m(2)/day, were analysed using a population pharmacokinetic approach (nonmem program)."	( Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Faure, C; Labbé, L; Litalien, C; Mouksassi, MS; Nguyen, B; Pettersen, G; Théorêt, Y, 2009)	0.62
" The developed assay method was applied to a pharmacokinetic study in human volunteers."	( Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K, 2009)	0.58
" The plasma profiles were evaluated by non-compartmental and compartmental approaches, and the pharmacokinetic parameters were determined."	( Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. Colombo, P; Colomé, LM; Costa, TD; Guterres, SS; Hoffmeister, CR; Natalini, CC; Pohlmann, AR; Raffin, RP; Rossi, A; Sonvico, F, 2010)	0.59
"The pharmacokinetic profile of pantoprazole granules was assessed in neonates and preterm infants with gastroesophageal reflux disease (GERD) in a multicenter, randomized, open-label trial."	( Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Comer, GM; Maguire, MK; Meng, X; Rath, N; Stewart, DL; Sullivan, SE; Tammara, B; Ward, RM, 2010)	0.89
" While the half-life was longer, accumulation did not occur."	( Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Comer, GM; Maguire, MK; Meng, X; Rath, N; Stewart, DL; Sullivan, SE; Tammara, B; Ward, RM, 2010)	0.6
" Third compartment pH was recorded and plasma samples were taken for pharmacokinetic analysis."	( Efficacy and pharmacokinetics of pantoprazole in alpacas. Campbell, NB; Davis, JL; Foster, DM; Gerard, MP; Smith, GW; Smith, SM, )	0.41
" Pharmacokinetic analysis demonstrated that pantoprazole had a short elimination half-life (0."	( Efficacy and pharmacokinetics of pantoprazole in alpacas. Campbell, NB; Davis, JL; Foster, DM; Gerard, MP; Smith, GW; Smith, SM, )	0.67
" Pantoprazole pharmacokinetic parameters appear to be similar in pediatric patients compared to adults when allometrically scaled."	( Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. Comer, G; Gastonguay, MR; Knebel, W; Meng, X; Tammara, B; Udata, C, 2011)	1.55
"To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study."	( Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011)	0.91
"In studies 1 and 2, 21 and 24 patients, respectively, were enrolled for pharmacodynamic evaluation."	( Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Comer, GM; David, ES; Fu, C; Furmaga-Jablonska, W; Kierkus, J; Maguire, MK; Rath, N; Stewart, DL; Sullivan, JE; Wang, W, 2011)	0.66
" The aim of these studies was to characterize the pharmacokinetic (PK) profile of single and multiple doses of pantoprazole delayed-release tablets in pediatric patients with GERD aged 6 to 11 years (study 1) and 12 to 16 years (study 2)."	( A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. Bishop, P; Comer, GM; James, LP; Katz, MH; Kearns, GL; Maguire, MK; Meng, X; O'Gorman, MA; Rath, N; Tammara, B; Ward, RM, 2011)	0.81
" Blood sampling for pharmacokinetic assessment was conducted 0-120 h post diazepam application and data were analyzed using a model-independent approach and ANOVA."	( Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Bethke, TD; Drewelow, B; Reitmeir, P; Schaffler, K, 2010)	0.62
" This method offered good precision and accuracy and was successfully applied to the pharmacokinetic and bioequivalence studies of 40 mg of enteric-coated pantoprazole in 20 healthy Chinese volunteers."	( Quantification of pantoprazole in human plasma using LC-MS/MS for pharmacokinetics and bioequivalence study. Ding, MJ; Fan, HW; Li, Y; Lu, ZY; Ma, J; Wang, S; Wu, XL; Xu, HJ; Zhou, XM; Zou, JJ, 2011)	0.9
"Safety concerns have recently emerged based on a drug interaction between clopidogrel and proton pump inhibitors leading to reduced pharmacodynamic effects."	( Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, MK; Pham, JP; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.66
"Pantoprazole therapy used at high doses is not associated with modulation of the pharmacodynamic effects of clopidogrel, irrespective of timing of drug administration."	( Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, MK; Pham, JP; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	2.1
"The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD)."	( Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Adcock, KG; Comer, GM; Giblin, J; Kierkus, J; Maguire, MK; Meng, X; Rath, N; Sullivan, JE; Tammara, BK; Ward, RM, 2011)	0.82
" Descriptive statistics were calculated for pharmacokinetic parameters."	( Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Adcock, KG; Comer, GM; Giblin, J; Kierkus, J; Maguire, MK; Meng, X; Rath, N; Sullivan, JE; Tammara, BK; Ward, RM, 2011)	0.59
"3%, prolongation of terminal half-life (t(½)) by 572%, a rise in area under the concentration-time curve (AUC) and mean residence time (MRT) by 506% and 259% respectively."	( CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Adamiak-Giera, U; Drozdzik, M; Gawrońska-Szklarz, B; Gornik, W; Kaldonska, M; Kurzawski, M; Wyska, E, 2012)	0.62
" The pharmacodynamic effects of both proton pump inhibitors were not significantly different between BMI groups, and no evidence was found for an interaction between BMI and treatment."	( On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013)	0.39
"Three randomized, open-label, two-way crossover pharmacokinetic studies were conducted in healthy subjects."	( Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Harris, R; Padhi, D; Sullivan, JT, 2014)	0.65
"The pharmacokinetic parameters of cinacalcet were not affected by co-administration of CaCO(3), sevelamer HCl or pantoprazole."	( Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Harris, R; Padhi, D; Sullivan, JT, 2014)	0.86
" Blood samples were collected for pharmacokinetic studies."	( A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Bedard, PL; Brana, I; Chen, EX; Douglas, S; Haines, C; Lee, C; Ocana, A; Razak, AR; Siu, LL; Tannock, IF; Wang, L, 2014)	0.73
" The method was demonstrated with acceptable accuracy, precision, selectivity, and stability and the method was applied to support a pharmacokinetic study of a phase I clinical trial of racemic pantoprazole in healthy Chinese subjects."	( High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. Hong, Z; Jiang, H; Li, S; Liang, W; Liu, Y; Shen, X; Wang, Y, 2016)	0.84
" This method was applied to the stereoselective pharmacokinetic studies in human after intravenous administration of S-(-)-pantoprazole sodium injections."	( A chiral LC-MS/MS method for the enantioselective determination of R-(+)- and S-(-)-pantoprazole in human plasma and its application to a pharmacokinetic study of S-(-)-pantoprazole sodium injection. Chen, J; Jiao, H; Li, Y; Sun, L; Wang, Y; Xie, L; Yu, L; Yuan, Z; Zhang, H, 2017)	0.89
" Subjects were sampled for pharmacokinetic analysis and were monitored for 24-h intragastric pH prior to and 48-h intragastric pH after administration for the pharmacodynamic study."	( Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. Chen, J; Jiao, HW; Li, YQ; Meng, L; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Yu, L; Yu, LY; Yuan, ZQ; Zhang, HW; Zhang, XH, 2018)	0.73
" Elimination rate constant and half-life observed statistical difference from a single dose to multiple doses in 40 mg of S-(-)-PPZ groups."	( Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. Chen, J; Jiao, HW; Li, YQ; Meng, L; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Yu, L; Yu, LY; Yuan, ZQ; Zhang, HW; Zhang, XH, 2018)	0.73
" Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation."	( A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. Brian Smith, P; Cohen-Wolkowiez, M; Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Wu, H; Zhao, J, 2018)	0.95
"The objective of this study was to develop pediatric physiologically based pharmacokinetic (PBPK) models for pantoprazole and esomeprazole."	( Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. Burckart, GJ; Crentsil, V; Duan, P; Fisher, J; Gonzalez, D; Moore, JN; Wang, J; Wu, F; Zhang, L, 2019)	0.73
" The aim of this study was to evaluate the impact of 7-day repeated 40-mg doses of pantoprazole on the pharmacokinetic (PK) properties of a single 500-mg dose of fedratinib in healthy male subjects."	( A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. Krishna, G; Ogasawara, K; Palmisano, M; Vince, B; Xu, C; Zhang, M, 2020)	1.03
"This study aimed to evaluate the bioequivalence of 2 pantoprazole sodium enteric-coated tablet formulations, a generic formulation and a branded formulation, and to investigate their pharmacokinetic and safety profiles."	( Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects. Chen, H; Chen, Z; Gan, F; Huang, X; Rao, X, 2021)	1.12
"This method was successfully applied to a pharmacokinetic interaction study in Wistar rats."	( High-throughput LC-MS/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study. Chen, X; Hong, Z; Le, J; Li, S; Liao, Y, 2021)	0.86

Excerpt	Reference	Relevance
" Different mechanisms have to be considered as causes for potential drug-drug interactions."	( Lack of pantoprazole drug interactions in man. Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K, 1994)	0.72
" Various mechanisms have to be considered as causes for potential drug-drug interactions."	( Lack of pantoprazole drug interactions in man: an updated review. Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K, 1996)	0.73
" Various mechanisms have to be considered as causes for potential drug-drug interactions."	( Lack of pantoprazole drug interactions in man: an updated review. Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K, 1996)	0.73
" PPIs may interact with other drugs through numerous mechanisms."	( Proton pump inhibitors and their drug interactions: an evidence-based approach. Gerson, LB; Triadafilopoulos, G, 2001)	0.31
" No studies have yet compared the effects of different dosages of clarithromycin in combination with a proton pump inhibitor and amoxicillin in elderly patients."	( Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001)	0.51
") in combination with pantoprazole and amoxicillin in elderly patients."	( Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001)	0.82
" In situations in which both clopidogrel and a PPI are indicated, pantoprazole should be used since it is the PPI least likely to interact with clopidogrel."	( Drug-drug interaction between clopidogrel and the proton pump inhibitors. Mathews, KD; Norgard, NB; Wall, GC, 2009)	0.59
"We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma."	( Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Bouafia, F; Franchon, E; Gouraud, A; Pham, BN; Ranchon, F; Rioufol, C; Salles, G; Schwiertz, V; Vantard, N; Vial, T; You, B, 2011)	0.37
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
" No drug-drug interaction was observed."	( A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Bedard, PL; Brana, I; Chen, EX; Douglas, S; Haines, C; Lee, C; Ocana, A; Razak, AR; Siu, LL; Tannock, IF; Wang, L, 2014)	0.73
"Administration of high doses of pantoprazole in combination with doxorubicin is feasible."	( A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Bedard, PL; Brana, I; Chen, EX; Douglas, S; Haines, C; Lee, C; Ocana, A; Razak, AR; Siu, LL; Tannock, IF; Wang, L, 2014)	1.01
"SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin."	( [Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy]. Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014)	0.4
"To quantify the drug-drug interactions between dabigatran etexilate (DE) and proton pump inhibitors (PPI) and in particular the role of P-gp activity modulation."	( In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E, 2015)	0.42
" The model drug combination was metronidazole-pantoprazole-clarithromycin (MET-PAN-CLAR), which is widely used in clinic to treat ulcers caused by Helicobacter pylori."	( The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. Xing, J; Zang, M; Zhang, H; Zhu, M, 2015)	0.68
"The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA)."	( Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack. Lu, M, 2017)	0.92
"The objective of this study was to investigate effects of somatostatin combined with pantoprazole on serum C-reactive protein (CRP) and intercellular adhesion molecule-1 (ICAM-1) in severe acute pancreatitis (SAP) patients."	( Effects of Somatostatin Combined with Pantoprazole on Serum C-Reactive Protein and Intercellular Adhesion Molecule-1 in Severe Acute Pancreatitis. Huang, L; Liu, J; Liu, Y; Wang, G; Wang, J; Xu, X, 2019)	1.01
" When pantoprazole is used in combination with clobazam, dose reduction of clobazam should be considered, or significance of PPIs is seen to avoid adverse effects."	( Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study. Baddam, R; Gone, V; Pasupuleti, B; Prasad, OP; Venisetty, RK, 2020)	1.04

Excerpt	Reference	Relevance
" Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%)."	( Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. de Mey, C; Laroche, J; Meineke, I; Pue, MA, 1993)	1.52
" Pantoprazole formulated in an enteric-coated tablet displays high bioavailability and linear pharmacokinetics whether on single or multiple dose regimens."	( Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber, R; Kohl, B; Sachs, G; Senn-Bilfinger, J; Simon, WA; Sturm, E, 1995)	1.42
" Its absolute bioavailability is 77% and does not change upon multiple dosing."	( Pharmacokinetics of pantoprazole in man. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Steinijans, VW; Zech, K, 1996)	0.62
" Its absolute bioavailability is 77% and does not change upon multiple dosing."	( Pharmacokinetics of pantoprazole in man. Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Steinijans, VW; Zech, K, 1996)	0.62
" The primary pharmacokinetic characteristics for extent and rate of absorption were AUC(0-24h) and % PTF, respectively."	( Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Bliesath, H; Hartmann, M; Huber, R; Koch, HJ; Mascher, H; Steinijans, VW; Wurst, W, 1996)	1.74
" It has a high and constant bioavailability (approximately 77%) which does not change on multiple dosing, so that maximum blood levels are achieved after the first dose."	( Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Parsons, ME, 1996)	1.74
" However, the new omeprazole MUPS formulation still showed the well-known effect of initial low bioavailability increasing after repeated dosing."	( Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Ehrlich, A; Huber, R; Lücker, PW; Mascher, H; Sander, P; Wiedemann, A, )	0.37
" The bioavailability of pantoprazole is not altered by concomitant administration of food or antacids or with repeated dosing."	( Clinical experience with pantoprazole in gastroesophageal reflux disease. Avner, DL, 2000)	0.92
" Pantoprazole is well absorbed when administered as an enteric-coated, delayed-release tablet, with an oral bioavailability of approximately 77%."	( Pantoprazole: a new proton pump inhibitor. Jungnickel, PW, 2000)	2.66
" Pantoprazole is well absorbed, undergoes little first-pass metabolism, and has an absolute bioavailability of approximately 77%."	( Pantoprazole. Poole, P, 2001)	2.66
" However, decreased bioavailability may limit the value of intragastric delivery of PPIs because of the high frequency of gastric emptying problems in critically ill patients."	( Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Pisegna, JR, 2002)	0.31
" These include differences in PPI bioavailability and acid-suppressive effects."	( The clinical importance of proton pump inhibitor pharmacokinetics. Thomson, AB; Yacyshyn, BR, 2002)	0.31
"The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied."	( Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Abell, M; Ferron, GM; Getsy, J; Ku, S; Mayer, PR; Paul, J; Unruh, M, 2003)	0.94
" Bioavailability of intragastric-administered pantoprazole was 41%."	( Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals. Giguère, S; Ryan, CA; Sanchez, LC; Vickroy, T, 2005)	0.85
" In the in situ absorption study, the absorption rate constants were of no significant differences between the two enantiomers."	( Pharmacokinetic differences between pantoprazole enantiomers in rats. Xie, Z; Xu, H; Zhang, Y; Zhong, D, 2005)	0.6
"To compare the bioavailability of two pantoprazole (CAS 102625-70-7) formulations (40 mg pantoprazole enteric coated tablets) under fasted and fed conditions as well as to evaluate the dissolution profile in biorelevant media."	( Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Abib, E; Amarante, AR; Barros, FA; Bernasconi, G; Buranello, S; Calafatti, SA; Coelho, EC; Couto, JM; de Campos, DR; Júnior, JP; Marchioretto, MA; Meurer, EC; Silva, AR; Sommer, C; Vieira, NR, 2007)	0.86
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual variability of dabigatran pharmacokinetics in order to assess possible gender differences; and to assess the effect of pantoprazole coadministration on the bioavailability of dabigatran."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.52
" The effects of pantoprazole coadministration on the bioavailability of dabigatran were considered acceptable, and dose adjustment is not considered necessary."	( Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Fuhr, R; Rathgen, K; Stähle, H; Stangier, J, 2008)	0.69
"To assess the comparative bioavailability of two formulations (40 mg delayed-released [DR] tablet; test and reference) of pantoprazole (CAS 102625-70-7) in healthy volunteers of both sexes, with and without food."	( Comparative bioavailability study with two pantoprazole delayed-released tablet formulations administered with and without food in healthy subjects. De Nucci, G; Ilha, JO; Mendes, FD; Mendes, GD; Monif, T; Moreira, LD; Patni, AK; Reyer, S, 2008)	0.82
"The influence of pantoprazole 40 mg twice daily on the bioavailability of a single dose of mycophenolate mofetil 1000 mg or enteric-coated mycophenolate sodium is investigated in healthy volunteers."	( Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. Bucher, M; Faerber, L; Fischer, W; Kees, F; Raspé, A; Rupprecht, K; Schmidt, C; Schweda, F; Shipkova, M, 2009)	0.9
" The objective was to evaluate the relative bioavailability in dogs after the oral administration of soft agglomerates."	( Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. Colombo, P; Colomé, LM; Costa, TD; Guterres, SS; Hoffmeister, CR; Natalini, CC; Pohlmann, AR; Raffin, RP; Rossi, A; Sonvico, F, 2010)	0.59
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"In this prospective study we investigated the impact of the proton pump inhibitor (PPI) pantoprazole on the bioavailability of mycophenolic acid (MPA) after oral administration of enteric-coated mycophenolate sodium (EC-MPS; Myfortic) in heart or lung transplant recipients."	( The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. Behr, J; Kaczmarek, I; Kofler, S; Meiser, B; Müller, T; Reichart, B; Shipkova, M; Shvets, N; Sisic, Z; Sohn, HY; Steinbeck, G; Vogeser, M; Wolf, C, 2011)	0.89
" Its oral bioavailability is low and its intestinal absorption mechanism is not clear."	( Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers. Li, X; Lu, Y; Yin, Z; Yu, Y; Zhao, X, 2013)	0.39
" Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors."	( Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The co-administration of pantoprazole substantially reduced the bioavailability of MPA in patients maintained on MMF and had the opposite effect in patients maintained on EC-MPS, and therefore, clinicians should be cognizant of this drug interaction when prescribing the different MPA formulations."	( Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Boudville, N; Cervelli, M; Chakera, A; Chan, D; Dogra, G; Jeffrey, G; Joyce, D; Lim, WH; Ooi, E; Russ, G; Sallustio, B; Sunderland, A; Wong, G, 2020)	1.14

Excerpt	Relevance	Reference
" To define a dosage regimen for clinical trials we compared the effect of pantoprazole 40 and 60 mg daily on 24-h intragastric acidity and plasma gastrin concentrations using a double-blind, randomized, cross-over design."	( Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles. Broom, C; Hannan, A; Walt, RP; Weil, J, 1992)	0.86
"To compare pantoprazole 40 mg with omeprazole 20 mg as once daily dosing in the treatment of reflux oesophagitis (grades II and III)."	( A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Herz, R; Hölscher, AH; Mössner, J; Schneider, A, 1995)	0.99
" Antipyrine plasma concentrations were measured without pantoprazole (day 1), on the last day of chronic dosing with pantoprazole (day 12) and 48 hours after the last dose of pantoprazole (day 14) to differentiate between inhibition and induction, respectively."	( Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Bliesath, H; De Mey, C; Hartmann, M; Huber, R; Meineke, I; Steinijans, VW; Wurst, W, 1994)	1.98
"Sixteen healthy male subjects underwent two dosing periods."	( Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Bliesath, H; Hartmann, M; Huber, R; Lücker, PW; Lühmann, R; Theiss, U; Wurst, W, 1996)	0.5
" Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief."	( Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Bethke, TD; Botha, JF; Cariem, AK; Eloff, FP; Grundling, HD; Honiball, PJ; Marks, IN; Segal, I; Simjee, AE; Spies, SK; Theron, I; van Rensburg, CJ; van Zyl, JH, 1996)	0.59
"The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability."	( Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Bethke, TD; Botha, JF; Cariem, AK; Eloff, FP; Grundling, HD; Honiball, PJ; Marks, IN; Segal, I; Simjee, AE; Spies, SK; Theron, I; van Rensburg, CJ; van Zyl, JH, 1996)	0.99
" Antipyrine plasma concentrations were measured without pantoprazole (day 1), on the last day of chronic dosing with pantoprazole (day 12) and 48 hours after the last dose of pantoprazole (day 14) to differentiate between inhibition and induction, respectively."	( Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Bliesath, H; De Mey, C; Hartmann, M; Huber, R; Meineke, I; Steinijans, VW; Wurst, W, 1996)	1.98
" Increases in median pH over 24 h were observed in all subjects with both dosage regimens."	( Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Lühmann, R; Müssig, S; Schneider, A; Witzel, L, 1997)	0.57
"The study supports the recommendation of a once-daily morning dosage regimen of pantoprazole 40 mg in the treatment of acid-related diseases."	( Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Lühmann, R; Müssig, S; Schneider, A; Witzel, L, 1997)	0.79
" The AUCs of (-)-PAN after intravenous and oral dosing of (+)-PAN were 36."	( Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. Masubuchi, N; Tanaka, M; Yamazaki, H, 1998)	0.58
" Therefore, no dosage adjustment is needed when pantoprazole and cisapride are coadministered."	( Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. Ferron, GM; Fruncillo, RJ; Martin, PT; Mayer, PR; Paul, JC; Yacoub, L, 1999)	0.81
" At all measuring points during the 5-day dosing periods, 40 mg pantoprazole proved superior to 20 mg omeprazole in inhibiting meal-stimulated gastric acid secretion."	( Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Burkhardt, F; Dammann, HG, 1999)	1.98
") dosage form."	( Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000)	0.58
" pantoprazole dosage forms had similar favorable safety and tolerability profiles."	( Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000)	1.49
"No significant changes in the steady-state theophylline maximum plasma concentration (Cmax), time to Cmax (Tmax), minimum plasma concentration (Cmin), area under the plasma concentration-time curve over the 12-h dosing interval (AUC0-12), or apparent total oral clearance (CL/F) were observed within the two treatment groups when theophylline was administered alone or in combination with lansoprazole or pantoprazole."	( Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline. Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y, 2000)	0.71
" pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently."	( Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000)	0.31
" Intravenous pantoprazole is especially distinguished in its lack of clinically relevant drug interactions, and it requires no dosage adjustment for patients with renal insufficiency or with mild to moderate hepatic dysfunction."	( Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Metz, DC, 2000)	0.68
"The aim of this dose-response study was to compare the effectiveness of 10 mg, 20 mg, and 40 mg of pantoprazole with that of placebo tablets in the healing and symptom relief of gastroesophageal reflux disease associated with erosive esophagitis, and to determine the optimal dose."	( Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Bochenek, W; Richter, JE, 2000)	1.04
" The oral and IV formulations of pantoprazole are equally potent in inhibiting gastric acid secretion; thus, switching between formulations requires no dosage adjustments."	( Clinical experience with pantoprazole in gastroesophageal reflux disease. Avner, DL, 2000)	0.89
" Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment."	( Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Trépanier, EF, 2000)	0.92
" Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other."	( Switching between intravenous and oral pantoprazole. Pisegna, JR, 2001)	0.95
" and oral pantoprazole on gastric secretion and may be used to predict effects under other dosage regimens."	( Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. Ferron, GM; Mayer, PR; McKeand, W, 2001)	1.01
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pantoprazole are reviewed."	( Pantoprazole. Poole, P, 2001)	1.97
" The time of dosing and ingestion of meals may also influence the pharmacokinetics of these agents as well as their ability to suppress gastric acid secretion."	( Shortcomings of the first-generation proton pump inhibitors. Tytgat, GN, 2001)	0.31
" pantoprazole in patients who are unable to swallow solid dosage formulations."	( Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Chiu, YL; Freston, J; Lukasik, N; Pan, WJ; Täubel, J, 2001)	1.43
"Patients with impaired hepatic function usually require gastric acid-suppressant therapy but are at increased risk for drug interactions and may require dosage adjustments."	( Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001)	0.63
"This study sought to determine whether dosage adjustment of pantoprazole is required in patients with moderate or severe hepatic impairment by comparing the pharmacokinetic profile of pantoprazole in such patients with that in healthy slow metabolizers of pantoprazole, in whom no dosage adjustment is required."	( Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001)	0.88
"The pharmacokinetics and tolerability of pantoprazole were similar in patients with moderate hepatic impairment, patients with severe hepatic impairment, and healthy slow metabolizers of pantoprazole, in whom no dosage adjustment is required."	( Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001)	0.9
" Intravenous pantoprazole inhibited acid output in a dose-response fashion, with maximal inhibition (99."	( Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. Bochenek, WJ; Ferron, GM; Metz, DC; Paul, J; Pisegna, JR; Soffer, E; Turner, MB, 2002)	0.68
" These patients underwent a 24-hour intragastric pH-metry, measurement of basal acid output and of serum gastrin first while receiving their usual therapy and second after 7 to 10 days of pantoprazole treatment at a mean dosage of 116 mg/day (range: 40-200 mg/day)."	( Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Mignon, M; Ramdani, A; Samoyeau, R, 2002)	0.91
" This suggests that for stress ulcer prophylaxis, intermittent dosing with an intravenous proton pump inhibitor may be an alternative to high-dose continuous infusions of a histamine-2-receptor antagonist."	( Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Steinberg, KP, 2002)	0.31
" Available data indicate that PPIs appear to have similar potency on a milligram basis, and that omeprazole and lansoprazole are more frequently double dosed than pantoprazole."	( The clinical importance of proton pump inhibitor pharmacokinetics. Thomson, AB; Yacyshyn, BR, 2002)	0.51
" If the results were improved but still abnormal, the dosage was doubled and pH monitoring was repeated."	( Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003)	0.53
"To compare the effectiveness of two different pantoprazole dosage regimens (20 and 40 mg/day), in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis."	( Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. Brito, EM; Castro, Lde P; Coelho, LG; Moretzsohn, LD; Reis, MS, )	0.63
"Pantoprazole dosage regimens of 20 mg/day and 40 mg/day provide equivalent effectiveness in controlling symptoms and healing esophageal lesions of mild esophagitis."	( Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. Brito, EM; Castro, Lde P; Coelho, LG; Moretzsohn, LD; Reis, MS, )	1.82
" Gastrin probably plays an important role in gastric tumorgenesis, and long-term dosing with ciprofibrate results in enterochromaffin-like (ECL) cell carcinoids in the oxyntic mucosa of rats."	( Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study. Bendheim, MØ; Martinsen, TC; Skogaker, NE; Waldum, HL, 2003)	0.32
"We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics."	( Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. Beckerling, A; Gatz, G; Ulmer, HJ, 2003)	0.52
" The method was applied successfully for the analysis of pantoprazole in tablet dosage form."	( Determination of pantoprazole by adsorptive stripping voltammetry at carbon paste electrode. Radi, A, 2003)	0.9
"Rapid and consistent acid suppression on the first day of dosing may be important in treating acid-related disorders."	( Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M, 2003)	0.32
" The optimum assay conditions are investigated and the recovery of the cited drugs from their dosage forms ranges from 97."	( Validation of the spectrophotometric determination of omeprazole and pantoprazole sodium via their metal chelates. Abdel Razeq, SA; El-Abasawy, N; Fouad, MM; Ismail, MM; Salama, F, 2003)	0.55
" The use of differential pulse voltammetry for the determination of pantoprazole in pharmaceutical dosage forms and human plasma using a glassy carbon electrode has been examined."	( Differential pulse anodic voltammetric determination of pantoprazole in pharmaceutical dosage forms and human plasma using glassy carbon electrode. Erk, N, 2003)	0.8
" The voltammetric procedure was applied successfully to give a rapid and precise assay of pantoprazole in a tablet dosage form."	( Square-wave adsorptive cathodic stripping voltammetry of pantoprazole. Radi, A, 2003)	0.79
" This dosage was significantly different for duodenal ulcer (40."	( [Cost-minimization study on the prescription of intravenous proton pump inhibitors: pantoprazole versus omeprazole]. García González, F; Hedo Aparicio, G; Soler Company, E, )	0.36
"To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)."	( Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Lind, T; Röhss, K; Wilder-Smith, C, 2004)	0.76
"Once-daily dosing with esomeprazole 40 mg intravenously provides faster and more pronounced intragastric acid control than pantoprazole 40 mg intravenously."	( Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Ahlbom, H; Bondarov, P; Hallerbäck, B; Röhss, K; Svedberg, LE; Wilder-Smith, CH, 2004)	0.75
" Daytime heartburn, night-time heartburn and regurgitation were significantly better controlled with pantoprazole (with a dose-response at most time-points)."	( Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004)	1.98
" These pharmacokinetic characteristics confirm the suitability of this oral solid dosage form for use in future clinical trials."	( Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Ahnfelt, L; Dahl, OE; Eriksson, BI; Nehmiz, G; Rathgen, K; Stähle, H; Stangier, J; Svärd, R, 2005)	0.33
"To compare the ability of immediate-release omeprazole with pantoprazole to control nocturnal gastric acidity, when they were dosed once daily and twice daily."	( Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005)	0.79
"Dosed once daily at bedtime, immediate-release omeprazole reduced nocturnal gastric acidity to a degree not observed with once daily dosing of delayed-release proton-pump inhibitors."	( Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Bagin, R; Castell, D; Goldlust, B; Hepburn, B; Major, J, 2005)	0.55
" Long-term dosing schedule (high dose or step-down dose) was based on current market data."	( Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005)	0.33
" The setting-specific appropriateness of the IV PPI indication and dosing regimen was determined."	( Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Bates, D; Kaplan, GG; McDonald, D; Panaccione, R; Romagnuolo, J, 2005)	0.61
" Both indication and dosing regimen were appropriate in 21%."	( Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Bates, D; Kaplan, GG; McDonald, D; Panaccione, R; Romagnuolo, J, 2005)	0.61
" Twenty-four-hour pH testing was performed on day 5 of each dosing period."	( Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Goldstein, JL; Liu, S; Miner, PB; Schlesinger, PK; Silberg, DG, 2006)	0.54
" Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy."	( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006)	0.33
"To determine the prevalence of sub-optimal proton pump inhibitor dosing in a community-based gastro-oesophageal reflux disease population."	( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006)	0.33
"One hundred patients on proton pump inhibitors referred for persistent gastro-oesophageal reflux disease symptoms were questioned about their proton pump inhibitor dosing habits and classified as optimal or sub-optimal dosers."	( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006)	0.33
"Forty-six percent dosed optimally."	( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006)	0.33
"In this study, 54% of patients dosed proton pump inhibitors sub-optimally and only 12% dosed in a manner that maximized acid suppression."	( Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006)	0.33
" The method could be successfully applied to the determination of pure, laboratory prepared mixtures and pharmaceutical dosage forms."	( Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products. El-Bardicy, MG; El-Sherif, ZA; El-Tarras, MF; Mohamed, AO, 2006)	0.54
" Healthy, Helicobacter pylori-negative adults were randomly assigned to 1 of 2 dosing sequences: pantoprazole IV followed by esomeprazole PO or pantoprazole IV followed by pantoprazole PO."	( Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Castell, DO; Liu, S; Miner, PB; Sostek, MB; Tutuian, R, 2006)	0.78
" The primary endpoint was a comparison of the inhibition of pentagastrin-stimulated maximum acid output (MAO) at steady state after once daily dosing for 1 week and 23 h after the last dose of pantoprazole granules and tablets."	( Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007)	1.04
" Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration."	( Long-term proton pump inhibitor use in children: a retrospective review of safety. Boyer, K; Tolia, V, 2008)	0.35
" Data collected included demographics, indication and dosing of pantoprazole, admitting team (surgery vs."	( Intravenous pantoprazole utilization in a level 1 trauma center. Edelman, DA; Patel, KR; Tyburski, JG; Zimmerman, LG, 2008)	0.96
" Appropriate indications and dosing of pantoprazole could eliminate the shortages seen at our institution."	( Intravenous pantoprazole utilization in a level 1 trauma center. Edelman, DA; Patel, KR; Tyburski, JG; Zimmerman, LG, 2008)	0.99
"In this study, the influence of CYP2C19 on both the pharmacokinetics and dynamics in Caucasian subjects after single and repeated dosing has been investigated."	( Effect of CYP2C192 and 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Franck, PF; Geus, WP; Hunfeld, NG; Kuipers, EJ; Mathot, RA; Mulder, PG; Touw, DJ; van Schaik, RH, 2008)	0.35
" 1/2 genotype showed a significant acid-inhibitory effect after repeated dosing with L15 and O10."	( Effect of CYP2C192 and 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Franck, PF; Geus, WP; Hunfeld, NG; Kuipers, EJ; Mathot, RA; Mulder, PG; Touw, DJ; van Schaik, RH, 2008)	0.35
" administration, whereas the AUC after oral dosing was unaltered."	( The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Beijnen, JH; Buckle, T; Oostendorp, RL; Schellens, JH; van Tellingen, O, 2009)	0.35
" This study set out to assess whether increasing the dosage of oral esomeprazole and pantoprazole improves acid control in GORD patients, and to compare the pharmacodynamic efficacy of esomeprazole and pantoprazole administered at different dosages."	( Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Backlund, A; Eckerwall, G; Fjellman, M; Lind, T; Röhss, K; Wilder-Smith, C, 2008)	0.84
"Comparative studies of proton pump inhibitors (PPIs) have revealed that acid reflux is influenced by PPI treatment, formulations and dosing regimens."	( Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G, 2008)	0.35
" All gastric fluid was aspirated through a nasogastric tube 1 h before dosing and through the postoperative period."	( Effect of preoperative intravenous pantoprazole in elective-surgery patients: a pilot study. Dorr, MB; Fogel, R; Jay Graepel, G; Karlstadt, RG; Norton, JA; Oh, DS; Pisegna, JR, 2009)	0.63
"Because of its unique pharmacokinetic properties, immediate-release omeprazole does not need to be dosed before a meal to control intragastric acidity."	( Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009)	0.35
"To compare the effects of prebreakfast dosing of immediate-release omeprazole 40 mg capsules, lansoprazole 30 mg capsules, and pantoprazole 40 mg tablets on 24-hour intragastric acidity."	( Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009)	0.56
"When dosed in the morning, immediate-release omeprazole provided significantly better control of 24-hour intragastric acidity than lansoprazole and pantoprazole."	( Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009)	0.55
"These results provide important information for physicians regarding selection of a starting dose and dosing regimens of pantoprazole for paediatric intensive care patients based on factors frequently encountered in this population."	( Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Faure, C; Labbé, L; Litalien, C; Mouksassi, MS; Nguyen, B; Pettersen, G; Théorêt, Y, 2009)	0.82
"To determine the plasma concentration of pantoprazole sodium by high performance liquid chromatography and its distribution in patients with different CYP2C19 genotypes in an attempt to provide experimental data for the clinical dosage adjustment of the drug."	( Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism. Jiang, W; Li, KQ; Lu, JR; Shao, JG; Sun, YY, 2009)	0.93
" In order to improve technological characteristics of the pantoprazole-loaded microparticles, soft agglomerates were prepared viewing an oral delayed release and gastro-resistant solid dosage form."	( Agglomerates containing pantoprazole microparticles: modulating the drug release. Colombo, P; Guterres, SS; Jornada, DS; Pohlmann, AR; Raffin, RP; Rossi, A; Sonvico, F, 2009)	0.9
" Breath samples were collected at 10-min intervals for 60 min after dosing with 100 mg [(13)C]-pantoprazole."	( [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M, 2009)	1.05
" The effects of P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2), and breast cancer resistance protein (BCRP) inhibitors on sulfasalazine bidirectional permeability were studied across Caco-2 cell monolayers, including dose-response analysis."	( Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Amidon, GL; Dahan, A, 2009)	0.35
" The literature suggests three possibilities to explain the inadequacy of the substitution: (a) biphasic metabolism where the raised pH in the stomach may prematurely inactivate the PPI, with an unpredictable effect, (b) differences in acid-resistant coating of the generic products, and (c) influence of multiple dosing of PPIs after several days' use."	( [Why some proton pump inhibitors are more equal than others]. Lekkerkerker, JF; Mulder, CJ; Otten, MH, 2009)	0.35
" The amount of drug absorbed after oral dosing was similar after reference or agglomerate administration, leading to a relative bioavailability of 108%."	( Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. Colombo, P; Colomé, LM; Costa, TD; Guterres, SS; Hoffmeister, CR; Natalini, CC; Pohlmann, AR; Raffin, RP; Rossi, A; Sonvico, F, 2010)	0.59
"To quantify the effect of blinded dosage reduction after long-term therapy on symptom control and quality of life while assessing pharmacological and placebo needs."	( Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2010)	0.36
"Measured from the daily placebo arm, 19% of the patients terminated treatment, 33% managed with 2-6 tablets/week, 38% needed a daily dosage and 10% needed more than a daily dosage in the long run."	( Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2010)	0.36
"The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial."	( A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. Cheng, YC; Chiang, MF; Hsu, WL; Hsu, YC; Lin, HJ; Perng, CL; Wang, CS; Wu, HT; Yang, TH, 2010)	0.59
" After a washout period of > 2 weeks, the subjects underwent a platelet aggregation test before and after dosing with 75 mg of clopidogrel for 7 days."	( [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Furuta, T; Iwaki, T; Umemura, K, 2010)	0.87
"In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods."	( Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J, 2010)	0.74
" However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy."	( Editorial: just how "difficult" is it to withdraw PPI treatment? Howden, CW; Kahrilas, PJ, 2010)	0.36
"The mean MMF dosage of the non-PPI patients was 770 (249) mg/12 h and 771 (291) mg/12 h in pantoprazole-treated patients (NS)."	( Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Bönisch-Schmidt, S; Dikow, R; Hug, F; Schaier, M; Scharpf, D; Schmitt, WH; Scholl, C; Schwenger, V; Sommerer, C; Zeier, M, 2010)	0.58
"Four randomized, placebo-controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between clopidogrel (300-mg loading dose/75-mg/day maintenance dose) and the proton-pump inhibitor (PPI) omeprazole (80 mg) when they are administered simultaneously (study 1); whether the interaction, if any, can be mitigated by administering clopidogrel and omeprazole 12 h apart (study 2) or by increasing clopidogrel to 600-mg loading/150-mg/day maintenance dosing (study 3); and whether the interaction applies equally to the PPI pantoprazole (80 mg) (study 4)."	( Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Angiolillo, DJ; Bergougnan, L; Cheng, S; Dubar, M; Gibson, CM; Hurbin, F; LaCreta, FP; Nicolas, O; Ollier, C; Perrin, L, 2011)	0.8
" Effective treatment with pantoprazole requires correct dosing and understanding of the drug's kinetic profile in children."	( A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. Bishop, P; Comer, GM; James, LP; Katz, MH; Kearns, GL; Maguire, MK; Meng, X; O'Gorman, MA; Rath, N; Tammara, B; Ward, RM, 2011)	0.9
" The optimum assay conditions were investigated and the recovery of the drugs from their dosage forms ranged from 99."	( Spectrophotometric determination of peptic ulcer sulfur-containing drugs in bulk form and in tablets. El-Tantawy, AS; Khalil, SM; Mohamed, GG; Nour El-Dien, FA, 2010)	0.36
" Furthermore, we advise to monitor closely erlotinib plasma concentrations and adjust the erlotinib dose accordingly when a clinically relevant interaction is suspected and no proper dosing guidelines are available."	( Erlotinib and pantoprazole: a relevant interaction or not? Beijnen, JH; Fanggiday, JC; Lankheet, NA; Malingré, MM; Staaks, GH; Ter Heine, R; Van Der Westerlaken, MM, 2010)	0.72
" The results indicated that the structures of omeprazole or pantoprazole and kinds of metal ions together affected the binding interaction with BSA, which may have relevant consequence in rationalizing dosage for patients with gastric ulcer."	( Differential effects of Cu(II) and Fe(III) on the binding of omeprazole and pantoprazole to bovine serum albumin: toxic effect of metal ions on drugs. Chen, X; Liu, Y; Peng, M; Shi, S; Zhang, Y, 2011)	0.84
" Twenty-four-hour intragastric pH was continuously monitored on days 1 and 5 of each dosing period."	( Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study. Gao, J; Gao, S; Gong, YF; Guo, XR; Li, Z; Li, ZS; Liao, Z; Liu, P; Zhan, XB, 2012)	0.62
"Twenty-five volunteers completed the 2 dosing periods."	( Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study. Gao, J; Gao, S; Gong, YF; Guo, XR; Li, Z; Li, ZS; Liao, Z; Liu, P; Zhan, XB, 2012)	0.62
"The optimal dosage of intravenous proton pump inhibitors (PPIs) for the prevention of peptic ulcer rebleeding remains unclear."	( Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. Chen, CC; Fang, YJ; Han, ML; Hsu, SJ; Hu, FC; Lee, JY; Lin, JT; Lin, TL; Liou, JM; Tseng, PH; Wang, HP; Wu, MS, 2012)	0.38
" Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration."	( A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Bari, Z; Fakheri, H; Sardarian, H, 2012)	0.38
"GORD patients who after long-term continuous treatment were able to use less than a daily PPI dose in a placebo-controlled trial were compared to patients who persisted in a daily dosage with respect to general, lifestyle and quality of life characteristics (SF-36 Health Survey) as well as psychological factors (Symptom Check List 90), symptom control on daily PPI (Quality of Life in Reflux and Dyspepsia questionnaire), disease and medication history."	( Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error. de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2013)	0.39
" These data do not support adapting the dosage of rabeprazole and pantoprazole according to BMI in GORD patients when administered as an on-demand therapy schedule."	( On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013)	0.63
" Due to its delayed onset of efficacy and the necessary slow titration of dosage for tolerability reasons prednisone is frequently added by clinicians to the initial prophylactic treatment of a cluster episode."	( Study protocol of Prednisone in episodic Cluster Headache (PredCH): a randomized, double-blind, placebo-controlled parallel group trial to evaluate the efficacy and safety of oral prednisone as an add-on therapy in the prophylactic treatment of episodic c Burmeister, J; Diener, HC; Holle, D; Obermann, M; Ose, C; Scherag, A, 2013)	0.39
" The method was successfully applied to the analysis of EMZ and PRZ in their commercial dosage forms and the results were in good agreement with those obtained with the comparison method."	( Enhanced spectrofluorimetric determination of esomeprazole and pantoprazole in dosage forms and spiked human plasma using organized media. Alaa, H; Belal, F; Sharaf El-Din, M; Tolba, MM, 2015)	0.66
" The proposed sensors displayed useful analytical characteristics for the determination of PAN and ITH in bulk powder, in laboratory prepared mixtures and in combined dosage forms with clear discrimination from several ions, sugars and some common drug excipients."	( Novel potentiometric application for the determination of pantoprazole sodium and itopride hydrochloride in their pure and combined dosage form. Abd El-Rahman, MK; El-Ragehy, NA; El-Zeany, BA; Ragab, MT; Ramadan, NK, 2015)	0.66
" However, effective dosing or scheduling of proton pump inhibitors for the prevention of delayed bleeding after endoscopic resection remains unclear."	( Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ, 2017)	0.46
"The dosage groups were set as followed: 20 mg of single and multiple intravenous administration of S-(-)-PPZ, 40 mg of single and multiple intravenous administration of S-(-)-PPZ or pantoprazole, and 80 mg of single dosage group of S-(-)-PPZ."	( Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. Chen, J; Jiao, HW; Li, YQ; Meng, L; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Yu, L; Yu, LY; Yuan, ZQ; Zhang, HW; Zhang, XH, 2018)	0.92
"To assess appropriate pantoprazole dosing for obese children, we conducted a prospective pharmacokinetics (PK) investigation of pantoprazole in obese children, a patient population that is traditionally excluded from clinical trials."	( Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Smith, PB; Wu, H; Zhao, J, 2018)	1.07
"LBW dosing of pantoprazole led to pantoprazole PK similar to nonobese peers."	( Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Smith, PB; Wu, H; Zhao, J, 2018)	1.11
" Until now investigations have mainly focused on dosage forms loaded with very stable drugs or model substances."	( Development of a dual extrusion printing technique for an acid- and thermo-labile drug. Brecht, I; Domsta, V; Kempin, W; Seidlitz, A; Semmling, B; Tillmann, S; Weitschies, W, 2018)	0.48
" Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation."	( A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. Brian Smith, P; Cohen-Wolkowiez, M; Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Wu, H; Zhao, J, 2018)	0.95
"To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity."	( Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Abdel-Rahman, S; Friesen, CA; Gaedigk, A; Kearns, GL; Leeder, JS; Pearce, RE; Shakhnovich, V; Weigel, J, 2019)	0.75
"To achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole."	( Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Abdel-Rahman, S; Friesen, CA; Gaedigk, A; Kearns, GL; Leeder, JS; Pearce, RE; Shakhnovich, V; Weigel, J, 2019)	0.72
" We aimed to prospectively compare the effects of continuous infusion and intermittent dosing with pantoprazole on preventing gastric ESD-related bleeding."	( Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection. Baek, DH; Jeon, HK; Kim, DU; Kim, GH; Lee, BE; Seo, JH; Song, GA, 2019)	0.98
"Intermittent dosing with pantoprazole is sufficient and cost-effective for the prevention of gastric ESD-related bleeding."	( Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection. Baek, DH; Jeon, HK; Kim, DU; Kim, GH; Lee, BE; Seo, JH; Song, GA, 2019)	1.07
" The physicians should more carefully interpret whether there is an essential indication before prescribing PPIs and, if there is, to approve the proper dosing for the situation."	( A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors. Türkeş, C, 2019)	0.51
"The dosage groups were set as follows: 30 mg single and multiple intravenous administrations of LPZ or R-LPZ, 40 mg single and multiple intravenous administrations of PPZ or S-PPZ."	( Comparison of the gastric acid inhibition function among lansoprazole, pantoprazole, and their respective stereoisomers in healthy Chinese subjects . Jiao, HW; Li, YQ; Liu, Y; Shen, YW; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Xu, YH; Yu, L; Zhang, HW; Zhang, XH, 2019)	0.75
" The administration of minitablets in a certain number of units allows for flexible dosing for a broad age group of paediatric patients, which is particularly important for modified-release drugs."	( Comparison of the coating process and Szczepanska, M; Sznitowska, M, 2019)	0.51
" In patients with clozapine monotherapy, smokers had a higher daily dosage of CLZ compared to non-smokers (mean dosage 363±181 vs."	( The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. Dammann, G; Gründer, G; Haen, E; Hiemke, C; Kuzin, M; Paulzen, M; Schoretsanitis, G, 2020)	0.84
"Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) - Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage forms and their cost."	( Qualimetric analysis of proton pump inhibitors in Ukraine. Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM, 2019)	0.71
" Further studies are warranted to optimize dosage and duration of the intervention."	( The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Blesl, A; Feldbacher, N; Horvath, A; Komarova, I; Leber, B; Rainer, F; Stadlbauer, V; Steinwender, M, 2020)	0.56
"We developed and validated a simple, convenient and reproducible method for simultaneous estimation of six proton-pump inhibitors (PPIs), omeprazole (OPZ), esomeprazole (EOPZ), lansoprazole (LPZ), pantoprazole (PPZ), rabeprazole (RPZ) and ilaprazole (IPZ) in pharmaceutical dosage forms by a single marker."	( Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use. Chen, F; Fang, B; He, X; Wang, S, 2020)	0.75
"The proposed method, which is selective, economical and accurate, was applied successfully for determination of the cited PPIs in their respective pharmaceutical dosage forms."	( Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use. Chen, F; Fang, B; He, X; Wang, S, 2020)	0.56
" These results may influence drug choice and dosing of similarly metabolized drugs and may be helpful for designing studies in similar clinical situations."	( Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Clodi, C; Herkner, H; Holzer, M; Jilma, B; Mueller, M; Poppe, M; Rechenmacher, M; Reiter, B; Schoergenhofer, C; Schriefl, C; Schwameis, M; Sunder-Plaßmann, R; van Hasselt, JGC; van Os, W; Weiser, C, 2022)	0.94

Role	Description
anti-ulcer drug	One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that inhibits H(+)/K(+)-exchanging ATPase, EC 3.6.3.10. Such compounds are also known as proton pump inhibitors.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzimidazoles	An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
sulfoxide	An organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Pantoprazole Action Pathway	10	13
Pantoprazole Metabolism Pathway	2	2

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	12.5893	0.0032	45.4673	12,589.2998	AID2517
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
Chain A, Cruzipain	Trypanosoma cruzi	Potency	39.8107	0.0020	14.6779	39.8107	AID1478
15-lipoxygenase, partial	Homo sapiens (human)	Potency	25.1189	0.0126	10.6917	88.5700	AID887
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	0.1883	0.0060	38.0041	19,952.5996	AID1159521
TDP1 protein	Homo sapiens (human)	Potency	25.1144	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	26.6514	0.1800	13.5574	39.8107	AID1460; AID1468
AR protein	Homo sapiens (human)	Potency	13.6360	0.0002	21.2231	8,912.5098	AID743035; AID743036; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	22.3872	0.0112	12.4002	100.0000	AID1030
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	8.2543	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	12.2494	0.0123	7.9835	43.2770	AID1346984; AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	33.1734	0.0013	10.1577	42.8575	AID1259252
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.0473	0.0015	30.6073	15,848.9004	AID1224849
pregnane X nuclear receptor	Homo sapiens (human)	Potency	17.7828	0.0054	28.0263	1,258.9301	AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	20.2509	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743079
G	Vesicular stomatitis virus	Potency	24.4289	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	11.2140	0.0010	8.3798	61.1304	AID1645840
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	8.7748	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	29.8493	0.0017	23.8393	78.1014	AID743083
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	28.1838	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	39.8107	0.3548	28.0659	89.1251	AID504847
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	15.8489	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0003	23.4451	159.6830	AID743065
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	26.3314	0.0006	27.2152	1,122.0200	AID743202; AID743219
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	31.6228	0.2512	15.8432	39.8107	AID504327
lamin isoform A-delta10	Homo sapiens (human)	Potency	1.2589	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Interferon beta	Homo sapiens (human)	Potency	24.4289	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	24.4289	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	24.4289	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	24.4289	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	1.5000	0.4000	3.1000	9.7000	AID721751
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	500.0000	0.2100	5.5537	10.0000	AID721750
Solute carrier family 22 member 3	Homo sapiens (human)	IC50 (µMol)	137.0000	0.0900	3.7277	9.5000	AID721749
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)	IC50 (µMol)	63.0000	7.8000	8.2570	8.7140	AID1342731
Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.7807	6.0000	AID146855
Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	17.9000	0.0002	2.3185	10.0000	AID679462
Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Indoleamine 2,3-dioxygenase 1	Mus musculus (house mouse)	IC50 (µMol)	109.0000	0.0060	1.6251	10.0000	AID717846
Fatty acid synthase	Homo sapiens (human)	IC50 (µMol)	36.2000	0.0077	2.4624	5.8000	AID1195927
Fatty acid synthase	Homo sapiens (human)	Ki	4.1000	0.2800	3.4467	5.9000	AID1195927
Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)	IC50 (µMol)	199.5260	0.0048	0.8134	6.0000	AID146855
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	271.6000	0.1600	3.9571	8.6000	AID721748; AID721752
Indoleamine 2,3-dioxygenase 2	Mus musculus (house mouse)	IC50 (µMol)	12.6000	1.5000	5.0875	8.2000	AID717845
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	16.2667	0.0100	2.7656	10.0000	AID721746; AID721747; AID721754
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	7.7500	0.0040	1.9666	10.0000	AID1873205; AID679623
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
citrulline metabolic process	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
regulation of systemic arterial blood pressure	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
arginine catabolic process	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
nitric oxide mediated signal transduction	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
negative regulation of cell population proliferation	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
negative regulation of vascular permeability	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
positive regulation of angiogenesis	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
nitric oxide metabolic process	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
negative regulation of cellular response to hypoxia	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
arginine metabolic process	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of the force of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
regulation of sodium ion transport	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
osmosensory signaling pathway	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
regulation of blood pressure	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
response to xenobiotic stimulus	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
negative regulation of glucocorticoid biosynthetic process	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
negative regulation of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
positive regulation of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
positive regulation of striated muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
relaxation of cardiac muscle	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
cellular response to steroid hormone stimulus	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
membrane repolarization	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
response to glycoside	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
intracellular calcium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
cell adhesion	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
regulation of gene expression	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signaling	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of ATP-dependent activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
sodium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein transport into plasma membrane raft	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
innate immune response	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
ATP metabolic process	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein stabilization	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
relaxation of cardiac muscle	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
cardiac muscle contraction	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein localization to plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
membrane repolarization	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
monoatomic cation transmembrane transport	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of calcium:sodium antiporter activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
positive regulation of P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
regulation of resting membrane potential	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
cellular response to steroid hormone stimulus	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
response to glycoside	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
cellular response to amyloid-beta	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
neuron projection maintenance	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
retina homeostasis	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
lateral ventricle development	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
third ventricle development	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
neuronal-glial interaction involved in hindbrain glial-mediated radial cell migration	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
photoreceptor cell maintenance	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
motor behavior	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
plasma membrane bounded cell projection organization	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
positive regulation of neuron projection development	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cell-substrate adhesion	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
positive regulation of ATP-dependent activity	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
protein stabilization	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
membrane repolarization	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
transport across blood-brain barrier	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
positive regulation of sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
positive regulation of potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
negative regulation of glial cell migration	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
osteoblast differentiation	Fatty acid synthase	Homo sapiens (human)
glandular epithelial cell development	Fatty acid synthase	Homo sapiens (human)
fatty acid metabolic process	Fatty acid synthase	Homo sapiens (human)
fatty acid biosynthetic process	Fatty acid synthase	Homo sapiens (human)
inflammatory response	Fatty acid synthase	Homo sapiens (human)
ether lipid biosynthetic process	Fatty acid synthase	Homo sapiens (human)
neutrophil differentiation	Fatty acid synthase	Homo sapiens (human)
monocyte differentiation	Fatty acid synthase	Homo sapiens (human)
mammary gland development	Fatty acid synthase	Homo sapiens (human)
modulation by host of viral process	Fatty acid synthase	Homo sapiens (human)
cellular response to interleukin-4	Fatty acid synthase	Homo sapiens (human)
establishment of endothelial intestinal barrier	Fatty acid synthase	Homo sapiens (human)
fatty-acyl-CoA biosynthetic process	Fatty acid synthase	Homo sapiens (human)
behavioral fear response	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of the force of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system process	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
amygdala development	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
olfactory cortex development	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
locomotion	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
negative regulation of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
positive regulation of heart contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
neurotransmitter uptake	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
potassium ion transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
sodium ion transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of smooth muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of striated muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of blood pressure	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
adult locomotory behavior	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
visual learning	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
response to auditory stimulus	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
neuronal action potential propagation	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of vasoconstriction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
L-ascorbic acid metabolic process	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
response to nicotine	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
locomotory exploration behavior	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
sodium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
response to potassium ion	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
negative regulation of striated muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
ATP metabolic process	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of glutamate uptake involved in transmission of nerve impulse	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
relaxation of cardiac muscle	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cardiac muscle contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cellular response to mechanical stimulus	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cellular response to steroid hormone stimulus	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
potassium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
membrane repolarization	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
monoatomic cation transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
transport across blood-brain barrier	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
negative regulation of calcium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
negative regulation of calcium:sodium antiporter activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
response to glycoside	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
positive regulation of ATP-dependent activity	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
sodium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
protein stabilization	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
potassium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
protein localization to plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
membrane repolarization	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
positive regulation of potassium ion transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
positive regulation of sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
positive regulation of potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
transmembrane transport	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
positive regulation of P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
regulation of sodium ion transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
monoatomic ion transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
potassium ion transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
sodium ion transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
cell surface receptor signaling pathway	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
spermatogenesis	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
fertilization	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
flagellated sperm motility	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
regulation of cellular pH	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
sodium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
regulation of membrane potential	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
establishment of localization in cell	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
potassium ion transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
transport across blood-brain barrier	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
proton transmembrane transport	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
sodium ion export across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
potassium ion import across plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
intracellular potassium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
intracellular sodium ion homeostasis	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
catalytic activity	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
dimethylargininase activity	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
metal ion binding	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
amino acid binding	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
ATP binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
phosphatase activity	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
ATP hydrolysis activity	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
potassium ion binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sodium ion binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
transmembrane transporter binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
protein heterodimerization activity	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
protein-folding chaperone binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
steroid hormone binding	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
ATPase activator activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein kinase binding	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
MHC class II protein complex binding	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein-macromolecule adaptor activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein heterodimerization activity	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
ATPase binding	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
amyloid-beta binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
ATP binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
ATP hydrolysis activity	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
metal ion binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
protein-folding chaperone binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
steroid hormone binding	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
ATPase activator activity	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
protein-macromolecule adaptor activity	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
protein heterodimerization activity	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
ATPase binding	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
RNA binding	Fatty acid synthase	Homo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activity	Fatty acid synthase	Homo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activity	Fatty acid synthase	Homo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activity	Fatty acid synthase	Homo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity	Fatty acid synthase	Homo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity	Fatty acid synthase	Homo sapiens (human)
protein binding	Fatty acid synthase	Homo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activity	Fatty acid synthase	Homo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activity	Fatty acid synthase	Homo sapiens (human)
fatty acyl-[ACP] hydrolase activity	Fatty acid synthase	Homo sapiens (human)
phosphopantetheine binding	Fatty acid synthase	Homo sapiens (human)
cadherin binding	Fatty acid synthase	Homo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activity	Fatty acid synthase	Homo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity	Fatty acid synthase	Homo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activity	Fatty acid synthase	Homo sapiens (human)
fatty acid synthase activity	Fatty acid synthase	Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
steroid binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
ATP binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
phosphatase activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
ATP hydrolysis activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
potassium ion binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
sodium ion binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
protein heterodimerization activity	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
protein-folding chaperone binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
steroid hormone binding	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
ATPase activator activity	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
protein-macromolecule adaptor activity	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
ATPase binding	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
ATPase activator activity	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
protein-macromolecule adaptor activity	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
sodium channel regulator activity	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activity	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
protein binding	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
ATP binding	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
ATP hydrolysis activity	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activity	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
kinase binding	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
metal ion binding	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
cytosol	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
extracellular exosome	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
Golgi apparatus	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
postsynaptic density	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
basolateral plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
apical plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
lateral plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
T-tubule	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
axon	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
organelle membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sperm flagellum	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sarcolemma	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
melanosome	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
membrane raft	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
photoreceptor inner segment membrane	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
extracellular exosome	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
extracellular vesicle	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
protein-containing complex	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
sarcolemma	Sodium/potassium-transporting ATPase subunit alpha-1	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
intercalated disc	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
basolateral plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
apical plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
lateral plasma membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
T-tubule	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
organelle membrane	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
sperm flagellum	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
sarcolemma	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
extracellular exosome	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
extracellular vesicle	Sodium/potassium-transporting ATPase subunit beta-1	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
photoreceptor inner segment	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
endoplasmic reticulum	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
Golgi apparatus	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
axon	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
organelle membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
neuronal cell body membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
neuronal cell body	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
synapse	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
photoreceptor inner segment membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
neuron to neuron synapse	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
extracellular vesicle	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-3	Homo sapiens (human)
photoreceptor inner segment	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cytoplasm	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
external side of plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
apical plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
lateral plasma membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cell projection membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cell body membrane	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
cell periphery	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
astrocyte projection	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
astrocyte end-foot	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
neuron to neuron synapse	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit beta-2	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
Golgi apparatus	Fatty acid synthase	Homo sapiens (human)
cytosol	Fatty acid synthase	Homo sapiens (human)
plasma membrane	Fatty acid synthase	Homo sapiens (human)
membrane	Fatty acid synthase	Homo sapiens (human)
melanosome	Fatty acid synthase	Homo sapiens (human)
glycogen granule	Fatty acid synthase	Homo sapiens (human)
extracellular exosome	Fatty acid synthase	Homo sapiens (human)
cytoplasm	Fatty acid synthase	Homo sapiens (human)
cytoplasm	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
endosome	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
endoplasmic reticulum	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
caveola	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cell surface	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
intercalated disc	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
T-tubule	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
organelle membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cell projection	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
neuronal cell body	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
dendritic spine	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
extracellular vesicle	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
cell projection	Sodium/potassium-transporting ATPase subunit alpha-2	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
basolateral plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
apical plasma membrane	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
sperm flagellum	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
melanosome	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
extracellular exosome	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit beta-3	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
extracellular exosome	Sodium/potassium-transporting ATPase subunit gamma	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
membrane raft	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
sperm midpiece	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
photoreceptor cell cilium	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
rod photoreceptor outer segment	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
sodium:potassium-exchanging ATPase complex	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
plasma membrane	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
cell projection	Sodium/potassium-transporting ATPase subunit alpha-4	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1223342	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 3 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID717846	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1195927	Inhibition of purified recombinant FASN TE activity (unknown origin) using 4-MUH as substrate preincubated for 30 mins before substrate addition measured after 1 hr by fluorescence assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID717845	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1195928	Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1223377	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 3 to 200 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1873205	Inhibition of human ABCG2 expressed in human HEK293 cells membrane vesicles mediated transport of 3[H]-MTX for 2 mins using [3H]-methotrexate as substrate by rapid filtration technique	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID717840	Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID146855	In vitro evaluation for its ability to inhibit the Na+/K+ ATPase at pH 7.4.	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID24522	t1/2 is the time taken for the conversion of nicotinamides to isothiazolopyridine at pH=5.0	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID721747	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679462	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	2001	Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 364, Issue:6	Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
AID721746	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID721749	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721745	Ratio of Cmax unbound to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1348173	Anti-Trichomonas activity against Trichomonas vaginalis JT assessed as reduction in parasite growth after 24 hrs by haemocytometry	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Recent developments in anti-Trichomonas research: An update review.
AID721743	Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID24523	t1/2 is the time taken for the conversion of nicotinamides to isothiazolopyridine at pH=7.0	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID721742	Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID26125	pKa value (imidazole)	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID721748	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID25148	Half life at pH 7.4	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID1223345	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 50 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID679623	TP_TRANSPORTER: inhibition of MTX uptake in membrane vesicle from BCRP-expressing Sf9 cell	2004	Cancer research, Aug-15, Volume: 64, Issue:16	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID25146	t1/2 (pH 5)	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID721750	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID631830	Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites compound treated for 48 hrs measured after 48 hrs washout period	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Antiprotozoal activity of proton-pump inhibitors.
AID26312	pKa value (pyridine)	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID310878	Dissociation constant, pKa of the compound	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Recent advances in proton pump inhibitors and management of acid-peptic disorders.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID78913	In vitro evaluation for the inhibition of H+/K+ ATPase at pH < 3 in the gastric glands of isolated rabbit stomach.	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID631764	Antiprotozoan activity against Giardia intestinalis IMSS:0989:1 trophozoites compound treated for 48 hrs measured after 48 hrs washout period	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Antiprotozoal activity of proton-pump inhibitors.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID25144	t1/2 (pH 3)	1992	Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6	(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
AID679457	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells	2001	Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 364, Issue:6	Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID721737	Cmax in human at 40 mg, po after 7 days	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1223376	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 200 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID631763	Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites compound treated for 48 hrs measured after 48 hrs washout period	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Antiprotozoal activity of proton-pump inhibitors.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223343	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 10 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID679781	TP_TRANSPORTER: transepithelial transport in Bcrp-expressing MDCKII cells	2004	Cancer research, Aug-15, Volume: 64, Issue:16	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
AID1600080	Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 100 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectro	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223344	Permeability surface area for passive diffusion in MDCK2 cells assessed as transport at 30 uM after 0.5 to 1 hrs by HPLC method	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	169 (12.23)	18.2507
2000's	565 (40.88)	29.6817
2010's	524 (37.92)	24.3611
2020's	124 (8.97)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	476 (32.45%)	5.53%
Reviews	139 (9.48%)	6.00%
Case Studies	163 (11.11%)	4.05%
Observational	12 (0.82%)	0.25%
Other	677 (46.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (186)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine [NCT00950339]	Phase 4	63 participants (Actual)	Interventional	2009-08-31	Completed
A Multicenter, Open-Label, PK, PD and Safety Study of Pantoprazole Delayed-Release Granules Administered as a Suspension in Neonates and Preterm Infants With a Clinical Diagnosis of GERD [NCT00362609]	Phase 3	59 participants (Actual)	Interventional	2006-07-31	Completed
Randomized Controlled Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease [NCT02533349]	Phase 3	200 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Effect of Digene Total on 24 Hrs Ambulatory Gastric ph in Pts Suffering From Acid Peptic Disorder After Single and Repeated Dosing. [NCT01214408]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Diseas [NCT00300755]	Phase 3	60 participants (Actual)	Interventional	2006-05-31	Completed
A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558) [NCT01358344]	Phase 1	173 participants (Actual)	Interventional	2010-08-31	Completed
Twice-a-day PPI, Tetracycline, Metronidazolequadruple Therapy With Pylera® or Lactobacillus Reuteri for Treatment naïve or for Retreatment of H. Pylori: Two Randomized Pilot Studies [NCT03925818]		99 participants (Actual)	Interventional	2017-08-29	Terminated(stopped due to Lactobacillus reuteri (Gastrus®) was not anymore available in the region)
Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, P [NCT01132638]	Phase 3	713 participants (Actual)	Interventional	2011-08-31	Completed
Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy [NCT03948477]	Phase 2	160 participants (Actual)	Interventional	2019-06-10	Completed
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin [NCT01146483]	Phase 1	16 participants (Actual)	Interventional	2010-04-30	Completed
the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function [NCT03910647]	Phase 2	200 participants (Anticipated)	Interventional	2019-12-31	Not yet recruiting
A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed [NCT01283919]	Phase 1	42 participants (Actual)	Interventional	2004-10-31	Completed
Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study [NCT01182597]	Phase 3	190 participants (Anticipated)	Interventional	2010-08-31	Recruiting
The Clinical Significance of Acid Rebound: Symptoms of Reflux After PPI Treatment in Patients With Functional Dyspepsia [NCT01373970]	Phase 4	184 participants (Actual)	Interventional	2011-05-31	Terminated
A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology [NCT03600974]		200 participants (Anticipated)	Observational	2019-02-01	Not yet recruiting
Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding [NCT05624229]	Phase 4	672 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
PhaseⅢ Study of A Multicenter, Randomized, Double-blind, Active-controlled to Evaluate of Efficacy /Safety as H. Pylori Eradication Effect Between Ilaprazole/Pantoprazole [NCT02084420]	Phase 3	323 participants (Actual)	Interventional	2012-12-31	Completed
[NCT02108756]		272 participants (Anticipated)	Interventional	2014-02-28	Recruiting
The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR) [NCT02123498]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to IRB not approved)
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors [NCT03094416]	Phase 4	66 participants (Actual)	Interventional	2018-07-30	Completed
Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule With and Without Coadministration of Pantoprazole as Well as Under the Influence of Food in Healthy Subjects. A Threeway Crossover, Randomised, Op [NCT02170610]	Phase 1	18 participants (Actual)	Interventional	2002-03-31	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 25, 50 or 100 mg BIBR 1048 MS Film-coated Tablet With and Without Pre-treatment With Pantoprazole to Healthy Subjects. Four Groups, 2-way Crossover, Randomised, Open Trial. [NCT02170766]	Phase 1	48 participants (Actual)	Interventional	2000-10-31	Completed
Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects [NCT02173730]	Phase 1	36 participants (Actual)	Interventional	2002-11-30	Completed
A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed [NCT01283932]	Phase 1	52 participants (Actual)	Interventional	2004-10-31	Completed
A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in [NCT01179646]	Phase 1	48 participants (Actual)	Interventional	2004-06-30	Completed
Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial [NCT01179724]		206 participants (Anticipated)	Interventional	2009-07-31	Recruiting
Pantoprazole for the Treatment of GERD Associated Symptoms Focusing on Sleep Disorders. [NCT00562094]		8,616 participants (Actual)	Observational	2007-10-31	Completed
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery [NCT00839488]	Phase 4	6 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study)
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days in Healthy Subjects. Intraindividual Comparison (3-way [NCT02170623]	Phase 1	12 participants (Actual)	Interventional	2002-02-28	Completed
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-wa [NCT02170896]	Phase 1	16 participants (Actual)	Interventional	2001-10-31	Completed
Bioavailability of BIBR 953 ZW After Multiple Oral Doses of 50 and 200 mg BIBR 1048 MS Film-coated Tablet Administered BIDfor 3 Days or 200 mg BIBR 1048 MS With and Without Pre-treatment With Pantoprazole to Healthy Volunteer Subjects. Two Groups, 2-way C [NCT02170740]	Phase 1	26 participants (Actual)	Interventional	1999-11-30	Completed
Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia [NCT04713969]	Phase 4	60 participants (Anticipated)	Interventional	2021-03-31	Recruiting
Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 30 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial [NCT02264106]	Phase 1	12 participants (Actual)	Interventional	1998-04-30	Completed
Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-wa [NCT02170636]	Phase 1	15 participants (Actual)	Interventional	2002-01-31	Completed
A Relative Bioavailability Study of Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions [NCT00835588]	Phase 1	100 participants (Actual)	Interventional	2003-12-31	Completed
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS). [NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study [NCT00709046]		150 participants (Anticipated)	Interventional	2008-01-31	Recruiting
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomit [NCT01129427]	Phase 1	66 participants (Actual)	Interventional	2009-08-31	Completed
The Effect of Esomeprazole Versus Pantoprazole on Serum Cyclosporine Levels and Renal Function in Stable Kidney Transplant Recipients: A Randomized Clinical Trial [NCT03812419]		47 participants (Actual)	Interventional	2016-01-05	Completed
A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours [NCT01163903]	Phase 1	24 participants (Actual)	Interventional	2010-07-31	Completed
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study [NCT01167101]		290 participants (Actual)	Interventional	2009-05-31	Completed
A Pharmacokinetic Study to Assess the Bioequivalence of a Single-Dose of KUDCO and Wyeth Pharmaceuticals (Protonix) 40 mg Pantoprazole Sodium Delayed-Release Tablet When Administered to Healthy Adult Volunteers Under Fed Conditions [NCT01179659]	Phase 1	150 participants (Actual)	Interventional	2005-09-30	Completed
Heart Issues of PantoPrazOle (HIPPO) [NCT00600041]	Phase 1	20 participants (Actual)	Interventional	2005-05-31	Completed
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection [NCT06050824]	Phase 4	200 participants (Actual)	Interventional	2022-07-21	Completed
Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course [NCT00713947]	Phase 4	0 participants (Actual)	Interventional	2008-04-30	Withdrawn(stopped due to no inclusion)
An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis [NCT00938366]	Phase 1	18 participants (Actual)	Interventional	2008-01-31	Completed
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders [NCT00830115]		1,045 participants (Actual)	Observational	2009-01-31	Completed
A Relative Bioavailability Replicated Crossover Study of Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions. [NCT00835393]	Phase 1	50 participants (Actual)	Interventional	2003-12-31	Completed
Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial [NCT00881413]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to problems in funding)
An Open Label, Randomised, Crossover Study of the Bioavailability of Oral BIRB 796 BS Tablets (30 mg Single Dose) With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers to Assess the Effect of Gastric pH on Absorption of BIRB 796 [NCT02209831]	Phase 1	22 participants (Actual)	Interventional	2001-11-30	Completed
Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 20 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial. [NCT02264119]	Phase 1	12 participants (Actual)	Interventional	1998-04-30	Completed
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication [NCT02547038]		352 participants (Actual)	Interventional	2015-02-28	Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of Two Different 50 mg Capsules of BIBR 1048 MS With and Without Coadministration of Pantoprazole to Healthy Subjects Relative to Solution. Two Groups, 3-way Crossover, Randomised, Open Trial [NCT02170805]	Phase 1	24 participants (Actual)	Interventional	2001-04-30	Completed
A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects [NCT04935112]	Phase 1	15 participants (Actual)	Interventional	2021-07-07	Completed
Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor [NCT02449941]		30 participants (Actual)	Observational	2014-03-31	Completed
A Randomized Trial of Stereotactic Radiosurgery Versus Decompressive Surgery Followed by Postoperative Radiotherapy in Metastatic Spinal Cord Compression [NCT02167633]		10 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Due to low accrual rate)
Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients [NCT03545243]	Phase 4	79 participants (Actual)	Interventional	2018-04-23	Completed
A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression [NCT00744419]	Phase 1	24 participants (Actual)	Interventional	2009-05-31	Completed
[NCT02290327]	Phase 3	91 participants (Actual)	Interventional	2015-05-31	Completed
Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-peptidase Inhibitor (Sitagliptin) and Proton Pump Inhibitor (Pantoprazole) to Prevent Beta-cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfu [NCT00768651]	Phase 2	8 participants (Actual)	Interventional	2008-10-31	Completed
"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery." [NCT02703896]	Phase 4	1,920 participants (Actual)	Interventional	2012-01-31	Completed
The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates [NCT00825630]	Phase 4	123 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study [NCT00857597]	Phase 3	60 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Study was terminated after unplanned interim analysis of single centre data and results were reported)
The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD) [NCT00674245]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2008-04-30	Completed
Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay [NCT01023360]	Phase 4	30 participants (Anticipated)	Interventional	2008-05-31	Recruiting
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes [NCT00681005]		178 participants (Actual)	Interventional	2006-04-30	Completed
Comparison Between Tailored Therapy Guided by a Non-invasive Antibiotic Susceptibility Test and Empiric Treatment for First-line Helicobacter Pylori Eradication in Patients With Dyspepsia: a Randomized Controlled Trial. [NCT04107194]	Phase 3	362 participants (Anticipated)	Interventional	2020-01-14	Recruiting
Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers [NCT00915239]		50 participants (Actual)	Interventional	2006-01-31	Completed
Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial [NCT00731601]	Phase 4	120 participants (Actual)	Interventional	2008-05-31	Completed
Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure [NCT00699361]	Phase 3	0 participants (Actual)	Interventional	2008-08-31	Withdrawn(stopped due to Study withdrawn for financial issues)
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer [NCT04217512]	Phase 3	60 participants (Anticipated)	Interventional	2019-05-01	Recruiting
[NCT02733640]		42 participants (Actual)	Interventional	2012-10-31	Completed
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects [NCT00930670]	Phase 4	320 participants (Actual)	Interventional	2009-06-30	Completed
Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study [NCT00843063]	Phase 4	161 participants (Actual)	Interventional	2004-08-31	Completed
Pantoprazole 20 mg/40 mg for the Treatment of Gastroesophageal Reflux Disease (GERD) [NCT00561730]		1,995 participants (Actual)	Observational	2007-10-31	Completed
A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD [NCT00141817]	Phase 3	41 participants (Actual)	Interventional	2005-08-31	Completed
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delaye [NCT01418443]	Phase 1	0 participants	Interventional		Completed
Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy [NCT02718261]	Phase 4	3,350 participants (Actual)	Interventional	2016-02-29	Completed
The Cross-Over Study to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Korean Men. [NCT01857609]	Phase 1	24 participants (Actual)	Interventional	2012-08-31	Completed
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication. [NCT00841854]	Phase 4	199 participants (Actual)	Interventional	2008-06-30	Completed
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis [NCT02555852]		4,238,504 participants (Actual)	Observational	2011-09-30	Completed
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid [NCT00001191]	Phase 2	0 participants	Interventional	1983-02-03	Completed
Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d. [NCT00161096]	Phase 3	276 participants	Interventional	2004-03-31	Active, not recruiting
A Multicenter, Randomized, Open Label, Single and Multiple Dose Study of the Pharmacokinetics and Pharmacodynamics of 2 Dose Levels of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged 1 Through 11 Months With Presumed GERD [NCT00259012]	Phase 3	67 participants (Actual)	Interventional	2005-11-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD. [NCT00365300]	Phase 3	129 participants (Actual)	Interventional	2006-09-30	Completed
Efficacy of DA-5204 (Stillen 2X®) for Patients With Gastroesophageal Reflux Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study [NCT03998969]	Phase 3	70 participants (Actual)	Interventional	2016-06-01	Completed
Clopidogrel Proton-Pump Inhibitors Study [NCT01016717]	Phase 4	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to Since the published data resolved the study goals we decided not to start it)
A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects [NCT01882296]	Phase 1	40 participants (Anticipated)	Interventional		Not yet recruiting
The Effect of Obesity on the Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD [NCT01887743]	Phase 1	71 participants (Actual)	Interventional	2013-06-30	Completed
Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los An [NCT00246909]	Phase 4	600 participants	Interventional	2005-11-30	Completed
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" [NCT02028234]	Phase 4	150 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
A Randomized Controlled Trial: Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection [NCT04621487]		80 participants (Actual)	Interventional	2019-01-15	Completed
A Muliticenter, Open Label Safety Study of 2 Doses of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed GERD [NCT00868296]	Phase 3	58 participants (Actual)	Interventional	2006-03-31	Completed
Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding [NCT02757703]	Phase 4	150 participants (Actual)	Interventional	2010-05-31	Completed
Aspirin as Adjuvant Therapy in Young Psychotic Patients [NCT02685748]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2017-07-20	Completed
[NCT00625274]	Phase 4	100 participants (Anticipated)	Interventional	2004-06-30	Completed
Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced [NCT02788123]	Phase 4	9 participants (Actual)	Interventional	2017-03-03	Terminated(stopped due to Internal reassessment of the medicinal product development strategy by Sponsor)
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delaye [NCT01418417]	Phase 1	0 participants	Interventional		Completed
AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY [NCT02401035]	Phase 4	19 participants (Actual)	Interventional	2017-05-09	Terminated(stopped due to Study was terminated early due to the infeasibility of enrolling the required number of participants per protocol in the 1 <2 years of age cohort.)
A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD [NCT00410592]	Phase 4	90 participants (Anticipated)	Interventional	2006-10-31	Completed
An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole ( [NCT01847404]	Phase 1	24 participants (Actual)	Interventional	2013-05-14	Completed
An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole ( [NCT01847417]	Phase 1	24 participants (Actual)	Interventional	2013-05-16	Completed
The Usefulness of Melatonin Supplementation in Postmenopausal Women With Helicobacter Pylori-associated Dyspepsia [NCT04352062]		152 participants (Actual)	Interventional	2011-01-09	Completed
An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between the Altana Formulation of Pantoprazole Delayed-Release Granules and the Wyeth Formulation of Pantoprazole Delayed-Release Granules in Healthy Subjects. [NCT00383916]	Phase 1	0 participants	Interventional	2006-10-31	Completed
Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial [NCT02929563]	Phase 3	116 participants (Actual)	Interventional	2017-01-09	Completed
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms [NCT00449813]	Phase 4	40 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Inclusion-rate does not seem feasible anymore to obtain te required number of patients before the end of the trial.)
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 [NCT01654705]		80 participants (Actual)	Interventional	2009-09-30	Completed
Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test [NCT04022837]	Phase 2	200 participants (Anticipated)	Interventional	2019-11-01	Not yet recruiting
Vonoprazan vs. Pantoprazole in the Prevention of Post Endoscopic Band Ligation Ulcer/Bleeding in Portal Hypertensive Patients: A Randomized Controlled Trial [NCT05227833]	Phase 3	284 participants (Actual)	Interventional	2022-02-15	Completed
AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE E [NCT04821310]	Phase 2	110 participants (Anticipated)	Interventional	2022-01-13	Recruiting
A Multicenter, Randomized, Open-Label, Single And Multiple Dose Study Of The Pharmacokinetics And Safety of Two Dose Levels of Pantoprazole Sodium Tablets In Adolescents Aged 12 Through 16 Years With A Clinical Daignosis Of GERD. [NCT00367614]	Phase 3	20 participants (Anticipated)	Interventional	2007-01-31	Completed
A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn [NCT00237367]	Phase 4	52 participants (Actual)	Interventional		Completed
The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gastrointestinal Bleeding in ACS Patients With Hp Infection and Coronary Stents: an Open-label, Randomized, Controlled Trial [NCT04728516]	Phase 4	2,600 participants (Anticipated)	Interventional	2021-08-10	Not yet recruiting
Evaluation of the Efficacy of Different Duration of a Proton Pump Inhibitor in the Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting [NCT03908593]	Phase 4	232 participants (Anticipated)	Interventional	2019-10-14	Active, not recruiting
A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis [NCT00133770]	Phase 4	20 participants (Actual)	Interventional	2004-07-31	Completed
[NCT02274961]	Phase 3	174 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial [NCT00403364]	Phase 2/Phase 3	300 participants	Interventional	2003-07-31	Completed
Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial [NCT04697641]		202 participants (Actual)	Interventional	2017-09-01	Completed
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study. [NCT01477320]		124 participants (Actual)	Interventional	2013-09-30	Completed
Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole [NCT00668902]		25 participants (Actual)	Interventional	2007-03-31	Completed
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis [NCT01524757]		48 participants (Anticipated)	Interventional	2012-03-31	Not yet recruiting
A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer [NCT00037570]	Phase 2	12 participants (Actual)	Interventional	2000-11-30	Completed
An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis [NCT00040495]	Phase 3	149 participants (Actual)	Interventional	2001-04-30	Completed
A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 mg or Pantoprazole 40 mg Following Once Daily Infusion of Intravenous Pan [NCT00206050]	Phase 4	40 participants	Interventional	2004-09-30	Completed
Compare 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth on Helicobacter Pylori Eradication [NCT03321773]		440 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor [NCT00161200]	Phase 3	60 participants	Interventional	2002-12-31	Terminated(stopped due to slow accrual)
Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks [NCT00163306]	Phase 3	1,200 participants	Interventional	2005-05-31	Completed
A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis. [NCT00195208]	Phase 3	97 participants (Actual)	Interventional	2005-06-30	Completed
A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea [NCT02159976]		390 participants (Actual)	Interventional	2014-07-31	Completed
Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial [NCT02541864]		330 participants (Actual)	Interventional	2013-07-31	Completed
Comparing 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy on Helicobacter Pylori Eradication [NCT04566211]		440 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications [NCT02213887]	Phase 4	0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to Unable to recruit participants)
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects [NCT02214433]	Phase 1	70 participants (Actual)	Interventional	2014-08-31	Completed
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints [NCT00261300]	Phase 3	100 participants (Anticipated)	Interventional	2000-10-31	Completed
PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD [NCT00261339]	Phase 4	300 participants	Interventional	2005-08-31	Completed
Double Blinded, Randomized, Active Drug Comparative, Therapeutic Confirmatory Clinical Study to Evaluate the Efficacy and Safety of AGSPT201 in GERD Patients [NCT01400945]	Phase 3	154 participants (Actual)	Interventional	2009-12-31	Completed
Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study) [NCT00247715]		664 participants (Actual)	Interventional	2003-10-31	Completed
[NCT00279123]	Phase 4	0 participants	Interventional	2002-01-31	Completed
Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing [NCT00307944]	Phase 4	68 participants	Interventional	2004-08-31	Completed
Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD [NCT00304421]	Phase 4	23 participants (Anticipated)	Interventional	2004-01-31	Completed
COMPETITION: Investigation of Clinical Endpoints for Treatment-induced Gastroesophageal Reflux Disease (GERD) Symptom Changes [NCT00336219]	Phase 3	628 participants (Actual)	Interventional	2006-08-31	Completed
Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks [NCT00312806]	Phase 3	2,000 participants (Anticipated)	Interventional	2006-05-31	Completed
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor: A Prospective Randomized Controlled Trial [NCT06154226]	Phase 4	100 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Phase IIIb, Randomized, Triple-blinded and Crossover Study to Evaluate the Effect of Magnesium Pantoprazole 20mg Bid Versus Magnesium Pantoprazole 40mg qd on Intragastric Acid Inhibition Assessed by pHmetry, in Healthy Volunteers [NCT01499693]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to [NCT01654718]		40 participants (Actual)	Interventional	2008-10-31	Completed
Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients. [NCT01670552]	Phase 3	490 participants (Actual)	Interventional	2016-02-17	Completed
[NCT01710462]	Phase 3	0 participants (Actual)	Interventional	2013-08-31	Withdrawn(stopped due to Change of company's strategy)
Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials [NCT01735227]	Phase 4	620 participants (Anticipated)	Interventional	2012-11-30	Not yet recruiting
Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma: A Randomized Prospective Double-blinded Study. [NCT01744314]		150 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA) [NCT01748500]	Phase 2	21 participants (Actual)	Interventional	2013-01-31	Completed
An Open-label, Randomized Study to Evaluate Pharmacokinetic Interaction, Pharmacodynamics and Safety After Multiple Oral Dosing of CJ-12420 and Amoxicillin/Clarithromycin in Healthy Subjects [NCT03011996]	Phase 1	60 participants (Actual)	Interventional	2016-05-31	Completed
Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial. [NCT01737840]	Phase 4	66 participants (Actual)	Interventional	2012-10-31	Completed
Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms [NCT00829738]		4,188 participants (Actual)	Observational	2009-01-31	Completed
Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement. A Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up [NCT01410409]		100 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain [NCT01281501]	Phase 4	87 participants (Actual)	Interventional	2011-01-31	Completed
Physiologic Determinants of PPI Disposition in Children [NCT04248335]	Phase 4	150 participants (Anticipated)	Interventional	2018-07-03	Recruiting
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) [NCT02467621]	Phase 4	3,350 participants (Actual)	Interventional	2016-01-31	Completed
A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® [NCT01493557]	Phase 4	1,067 participants (Actual)	Interventional	2011-12-31	Completed
Effect of Histamine 2 Receptor Antagonist (H2RA) and Proton Pump Inhibitor (PPI) on the Positivity Rates and Clinical Outcomes of Coronavirus Disease-19 (COVID-19). [NCT04834752]		400,000 participants (Anticipated)	Observational	2021-05-01	Not yet recruiting
Structured Non-operative Treatment of Knee Osteoarthritis - a Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up [NCT01535001]		100 participants (Actual)	Interventional	2012-02-29	Completed
The Selection Criteria for Deciding Who Needs the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers [NCT02197039]		316 participants (Actual)	Observational [Patient Registry]	2011-08-31	Completed
Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes [NCT01541735]	Phase 2/Phase 3	14 participants (Actual)	Interventional	2012-01-31	Completed
CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD [NCT00325676]	Phase 4	639 participants (Actual)	Interventional	2006-06-30	Completed
Profi-Study: Symptom Reduction in Hospitalized Patients Suffering From Symptomatic Non-erosive or Erosive Gastroesophageal Reflux Disease Treated With Pantoprazole 20 or 40 mg o.d. for 7 Days [NCT00326027]	Phase 3	29 participants (Actual)	Interventional	2006-10-31	Completed
Efficacy and Safety of Thread Embedding Acupuncture Combined With PPI in Treating GERD [NCT05353933]		66 participants (Actual)	Interventional	2022-05-04	Completed
Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan [NCT01769365]	Phase 4	307 participants (Actual)	Interventional	2010-07-31	Completed
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients [NCT02432456]	Phase 4	153 participants (Actual)	Interventional	2015-09-30	Completed
Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery [NCT03038009]	Phase 4	0 participants (Actual)	Interventional	2018-10-31	Withdrawn(stopped due to A new registration has been submitted due to a redesign of the study protocol.)
Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses [NCT00374101]	Phase 3	450 participants	Interventional	2005-01-31	Completed
The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children and Adolescents [NCT02186652]	Phase 1	41 participants (Actual)	Interventional	2014-06-04	Completed
An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects [NCT03095547]	Phase 1	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to study no longer required in current format)
Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. [NCT02142712]	Phase 2	3 participants (Actual)	Interventional	2014-12-31	Completed
Re-EValuating the Inhibition of Stress Erosions: Prophylaxis Against Gastrointestinal Bleeding in the Critically Ill (The REVISE) Trial [NCT03374800]	Phase 3	4,800 participants (Actual)	Interventional	2018-07-09	Active, not recruiting
Baduanjin Program Effect on Geriatric Functional Dyspepsia [NCT05915520]		40 participants (Anticipated)	Interventional	2023-07-20	Recruiting
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy [NCT05251233]	Phase 2	240 participants (Anticipated)	Interventional	2022-04-21	Recruiting
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes [NCT02345239]	Phase 3	14 participants (Anticipated)	Interventional	2015-02-28	Not yet recruiting
Effects of PPI Therapy on Clopidogrel-Induced Antiplatelet Effects: A Randomized Study [NCT01170533]	Phase 1	20 participants (Actual)	Interventional	2009-03-31	Completed
Pharmacokinetic Cross-over Study to Evaluate the Influence of Pantoprazole on MPA Bioavailability Administered as Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Maintenance Renal Transplant Patients [NCT01801280]	Phase 4	20 participants (Actual)	Interventional	2012-01-31	Completed
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study) [NCT02359435]		440 participants (Actual)	Interventional	2012-10-31	Completed
Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma [NCT01848457]	Phase 2	13 participants (Actual)	Interventional	2013-04-30	Completed
An Open Label, Randomised, Single Dose, 3-way Cross Over Study to Investigate Relative Bioavailability and Food Effect on Different Formulations of BI 113608 in Healthy Male Subjects, Followed by Fixed Sequence Periods Investigating Influence of Pantopraz [NCT01703858]	Phase 1	15 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized Double-blinded Study to Evaluate Preincisional Dextromethorphan in Patients Undergoing Total Knee Arthroplasty and Its Effect on Postoperative Opioid Use [NCT02987920]	Phase 4	23 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to The surgeon changed pain control protocol for all patients. Continued enrollment impossible under approved protocol.)
Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection (CENERDD) [NCT02788591]		5 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to lack of accrual)
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed [NCT02235311]		3 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Difficulty recruiting and consenting participants)
Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients [NCT02466919]	Phase 4	114 participants (Actual)	Interventional	2014-05-31	Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial [NCT02551744]		101 participants (Actual)	Interventional	2012-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00141817 (8) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT00141817 (8) [back to overview]	Plasma Concentrations After Multiple Doses
NCT00141817 (8) [back to overview]	Terminal-Phase Volume of Distribution (Vz/F)
NCT00141817 (8) [back to overview]	Plasma Decay Half-Life (t1/2)
NCT00141817 (8) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT00141817 (8) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
NCT00141817 (8) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
NCT00141817 (8) [back to overview]	Apparent Oral Clearance (CL/F)
NCT00259012 (14) [back to overview]	Apparent Oral Clearance (CL/F)
NCT00259012 (14) [back to overview]	Normalized Area of Gastric Hydrogen Ion Activity Over Time
NCT00259012 (14) [back to overview]	Area Under the Concentration-time Curve (AUC)
NCT00259012 (14) [back to overview]	Disposition Half-life
NCT00259012 (14) [back to overview]	Peak Concentration (Cmax)
NCT00259012 (14) [back to overview]	Time to Peak Concentration (Tmax) Profile
NCT00259012 (14) [back to overview]	Intragastric pH
NCT00259012 (14) [back to overview]	Mean Intraesophageal pH
NCT00259012 (14) [back to overview]	Median Intraesophageal pH
NCT00259012 (14) [back to overview]	Median Intragastric pH
NCT00259012 (14) [back to overview]	Normalized Area of Esophageal Hydrogen Ion Activity Over Time
NCT00259012 (14) [back to overview]	Pantoprazole Plasma Concentration After Multiple-Dose Oral Administration
NCT00259012 (14) [back to overview]	Percentage of Time Intragastric pH Was >4
NCT00259012 (14) [back to overview]	Percentage of Time That Intraesophageal pH Was <4
NCT00300755 (4) [back to overview]	"Number of Patients With Healed Erosive Esophagitis (EE) at End of Study"
NCT00300755 (4) [back to overview]	Change in Individual Weekly Mean Frequency Score for Each Gastroesophageal Reflux Disease (GERD) Symptom Score From Baseline to Final Week
NCT00300755 (4) [back to overview]	Change in Individual Weekly Mean Score For Each Respiratory Symptom From Baseline
NCT00300755 (4) [back to overview]	Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)
NCT00362609 (4) [back to overview]	Area Under the Concentration-time Curve (AUC)
NCT00362609 (4) [back to overview]	Half Life
NCT00362609 (4) [back to overview]	Variance of Oral Bioavailability
NCT00362609 (4) [back to overview]	Apparent Oral Clearance (Cl/F)
NCT00365300 (1) [back to overview]	Number of Patients Withdrawn From Study Due to Lack of Efficacy.
NCT00561730 (11) [back to overview]	Assessment of the Efficacy of Pantoprazole 20 mg/40 mg at Final Visit
NCT00561730 (11) [back to overview]	Assessment of the Tolerability of Pantoprazole 20 mg/40 mg at Final Visit
NCT00561730 (11) [back to overview]	Patient's Assessment of Acid Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00561730 (11) [back to overview]	Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00561730 (11) [back to overview]	Patient's Assessment of Lower Abdominal/Digestive Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00561730 (11) [back to overview]	Patient's Assessment of Nausea During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00561730 (11) [back to overview]	Patient's Assessment of Upper Abdominal/Stomach Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00561730 (11) [back to overview]	Physician's Assessment of Acid Eructation
NCT00561730 (11) [back to overview]	Physician's Assessment of Heartburn
NCT00561730 (11) [back to overview]	Physician's Assessment of Painful Swallowing
NCT00561730 (11) [back to overview]	Patient's Assessment of Sleep Disturbances During the Last 24 Hours (Diaries; ReQuest™ in Practice)
NCT00562094 (8) [back to overview]	Assessment of Change of Quality of Sleep During Therapy With Pantoprazole
NCT00562094 (8) [back to overview]	Assessment of the Efficacy of Pantoprazole at Final Visit
NCT00562094 (8) [back to overview]	Assessment of the Severity of Epigastric Complaints/Epigastric Pain
NCT00562094 (8) [back to overview]	Assessment of the Severity of Eructation/Acid Eructation
NCT00562094 (8) [back to overview]	Assessment of the Severity of Heartburn
NCT00562094 (8) [back to overview]	Assessment of the Severity of Sensation of Fullness/Abdominal Distension
NCT00562094 (8) [back to overview]	Assessment of the Severity of Sleep Disturbances
NCT00562094 (8) [back to overview]	Assessment of the Tolerability of Pantoprazole at Final Visit
NCT00668902 (1) [back to overview]	DOBmax (Maximum Value of DOB)
NCT00768651 (2) [back to overview]	Insulin Independence After the 3 Month Washout Period
NCT00768651 (2) [back to overview]	The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy.
NCT00825630 (1) [back to overview]	Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.
NCT00829738 (13) [back to overview]	Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Painful Swallowing
NCT00829738 (13) [back to overview]	Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn
NCT00829738 (13) [back to overview]	Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Eructation/Sour Eructation
NCT00829738 (13) [back to overview]	Irritable Bowel Syndrome: Assessment of the Severity of Lower Abdominal Pain
NCT00829738 (13) [back to overview]	Irritable Bowel Syndrome: Assessment of the Severity of Diarrhoea
NCT00829738 (13) [back to overview]	Irritable Bowel Syndrome: Assessment of the Severity of Constipation
NCT00829738 (13) [back to overview]	Functional Dyspepsia Symptoms: Assessment of the Severity of Upper Abdominal Pain
NCT00829738 (13) [back to overview]	Functional Dyspepsia Symptoms: Assessment of the Severity of Sensation of Fullness
NCT00829738 (13) [back to overview]	Assessment of Pantoprazole at Final Visit: Efficacy Regarding Dyspeptic Symptoms
NCT00829738 (13) [back to overview]	Assessment of Pantoprazole at Final Visit: Efficacy Regarding Irritable Bowel Syndrome
NCT00829738 (13) [back to overview]	Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms
NCT00829738 (13) [back to overview]	Assessment of the Tolerability of Pantoprazole at Final Visit
NCT00829738 (13) [back to overview]	Functional Dyspepsia Symptoms: Assessment of the Severity of Nausea
NCT00830115 (13) [back to overview]	Patient's Assessment of General Well-being for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Patient's Assessment of Lower Abdominal/Digestive Complaints for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Patient's Assessment of Nausea for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Patient's Assessment of Sleep Disturbances for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Patient's Assessment of Upper-abdominal/Stomach Complaints for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Physician's Assessment of Acid Eructation
NCT00830115 (13) [back to overview]	Physician's Assessment of Heartburn
NCT00830115 (13) [back to overview]	Physician's Assessment of Painful Swallowing
NCT00830115 (13) [back to overview]	Physician's Assessment of Sleep Disturbances
NCT00830115 (13) [back to overview]	Patient's Assessment of Acid Complaints for the Last 24 Hours (Diaries)
NCT00830115 (13) [back to overview]	Assessment of the Efficacy of Pantoprazole at Final Visit
NCT00830115 (13) [back to overview]	Assessment of the Tolerability of Pantoprazole at Final Visit
NCT00835588 (3) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00835588 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00835588 (3) [back to overview]	Cmax - Maximum Observed Concentration - Pantoprazole in Plasma
NCT00868296 (2) [back to overview]	Growth Parameters Z-scores
NCT00868296 (2) [back to overview]	Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period
NCT00938366 (8) [back to overview]	Time to Reach the Maximum Plasma Concentration (Tmax) of Cladribine
NCT00938366 (8) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Cladribine
NCT00938366 (8) [back to overview]	Maximum Plasma Concentration (Cmax) of Cladribine
NCT00938366 (8) [back to overview]	Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/f) of Cladribine
NCT00938366 (8) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Cladribine
NCT00938366 (8) [back to overview]	Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of Cladribine
NCT00938366 (8) [back to overview]	Apparent Terminal Half-life (t1/2) of Cladribine
NCT00938366 (8) [back to overview]	Percentage of Subjects With Any Treatment Emergent Adverse Events (TEAEs), Serious AEs, AEs Leading to Death, and AEs Leading to Discontinuation
NCT01170533 (1) [back to overview]	Platelet Function as Assessed by the P2Y12 Reactivity Index
NCT01281501 (4) [back to overview]	Number of Participants That Have Overall Satisfaction on the Treatment
NCT01281501 (4) [back to overview]	Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment
NCT01281501 (4) [back to overview]	"Number of Participants in the Predefined Non-responders"
NCT01281501 (4) [back to overview]	"Number of Participants in the Predefined Responders"
NCT01410409 (8) [back to overview]	Change in the Five Subscales of KOOS From Baseline
NCT01410409 (8) [back to overview]	Proportion of Users of Pain Medication
NCT01410409 (8) [back to overview]	Change in 20-meter Walk From Baseline
NCT01410409 (8) [back to overview]	Change in KOOS4 From Baseline (Knee Injury and Osteoarthritis Outcome Score)
NCT01410409 (8) [back to overview]	Change in Timed Up & Go (TUG) From Baseline
NCT01410409 (8) [back to overview]	Serious Adverse Events Related to the Index Knee
NCT01410409 (8) [back to overview]	Weight Change in kg From Baseline
NCT01410409 (8) [back to overview]	Change in EQ-5D From Baseline
NCT01477320 (2) [back to overview]	Number of Subjects With GI Bleeding
NCT01477320 (2) [back to overview]	Number of Subjects With ICU-acquired C. Difficile Pseudomembranous Colitis.
NCT01493557 (10) [back to overview]	The Rate of Complete Effectiveness of Initial GIS Management Strategy
NCT01493557 (10) [back to overview]	Rates of Complete Effectiveness of GIS at Each Visit.
NCT01493557 (10) [back to overview]	Rate of Partial Effectiveness of Initial GIS Management Strategies
NCT01493557 (10) [back to overview]	Rate of Partial Effectiveness of Combined GIS Management Strategies
NCT01493557 (10) [back to overview]	Rate of Complete Effectiveness of Combined GIS Management Strategies
NCT01493557 (10) [back to overview]	Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies
NCT01493557 (10) [back to overview]	Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies
NCT01493557 (10) [back to overview]	Time Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom
NCT01493557 (10) [back to overview]	Rates of Partial Effectiveness of GIS at Each Visit.
NCT01493557 (10) [back to overview]	Rates of Complete or Partial Effectiveness of GIS at Each Visit.
NCT01535001 (8) [back to overview]	Change in the Five KOOS Subscale Scores From Baseline
NCT01535001 (8) [back to overview]	Change From Baseline in EQ-5D
NCT01535001 (8) [back to overview]	Weight Change in kg From Baseline
NCT01535001 (8) [back to overview]	Change From Baseline in Time From the Timed Up and Go
NCT01535001 (8) [back to overview]	Change From Baseline in KOOS4 (Knee Injury and Osteoarthritis Outcome Score)
NCT01535001 (8) [back to overview]	Change From Baseline in 20-meter Walk
NCT01535001 (8) [back to overview]	Number of Serious Adverse Events Reported at Index Knee
NCT01535001 (8) [back to overview]	Proportion of Users of Pain Medication
NCT01541735 (4) [back to overview]	First Phase of Insulin Secretion
NCT01541735 (4) [back to overview]	Second Phase of Insulin Secretion
NCT01541735 (4) [back to overview]	Total Insulin Secretion
NCT01541735 (4) [back to overview]	Glycated Hemoglobin A1C
NCT01703858 (3) [back to overview]	Area Under the Concentration-time Curve of the Analyte BI-113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01703858 (3) [back to overview]	Area Under the Concentration-time Curve of the Analyte BI-113608 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
NCT01703858 (3) [back to overview]	Maximum Measured Concentration of the Analyte BI-113608 in Plasma (Cmax)
NCT01737840 (2) [back to overview]	Need for Additional Drug
NCT01737840 (2) [back to overview]	Visual Analogue Scale Score
NCT01769365 (1) [back to overview]	Number of Participants With Complete Eradication of Helicobacter Pylori
NCT01776424 (8) [back to overview]	The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part
NCT01776424 (8) [back to overview]	The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
NCT01776424 (8) [back to overview]	The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part
NCT01776424 (8) [back to overview]	All-cause Mortality in LTOLE Part
NCT01776424 (8) [back to overview]	All-cause Mortality
NCT01776424 (8) [back to overview]	The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death
NCT01776424 (8) [back to overview]	The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death
NCT01776424 (8) [back to overview]	The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death
NCT01801280 (1) [back to overview]	Dose-normalized AUC of Mycophenolic Acid
NCT01848457 (6) [back to overview]	Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments
NCT01848457 (6) [back to overview]	Validating Urinary Biomarkers
NCT01848457 (6) [back to overview]	Bone Specific Alkaline Phosphatase (BSAP)
NCT01848457 (6) [back to overview]	Change in Tumor Volume
NCT01848457 (6) [back to overview]	Ototoxicity
NCT01848457 (6) [back to overview]	Patient Reported Outcome Survey (PROS)
NCT01887743 (5) [back to overview]	Unadjusted Pantoprazole Apparent Oral Clearance
NCT01887743 (5) [back to overview]	Recall of Breath Test to Discriminate the CYP2C19 Extensive Metabolizer (EM) From Intermediate Metabolizer (IM) Phenotype
NCT01887743 (5) [back to overview]	Harmonic Mean of Precision and Recall (F1) of the Breath Test to Discriminate the CYP2C19 Extensive Metabolizer (EM) From Intermediate Metabolizer (IM) Phenotype
NCT01887743 (5) [back to overview]	Pantoprazole Apparent Oral Clearance
NCT01887743 (5) [back to overview]	Precision of Breath Test to Discriminate the CYP2C19 Extensive Metabolizer (EM) From Intermediate Metabolizer (IM) Phenotype
NCT02142712 (2) [back to overview]	Glasgow Coma Scale (GCS)
NCT02142712 (2) [back to overview]	National Institutes of Health Stroke Severity (NIHSS) Scale
NCT02159976 (4) [back to overview]	Functional Dyspepsia Symptom Responses Rate
NCT02159976 (4) [back to overview]	Counts of Participants With Successful H. Pylori Eradication
NCT02159976 (4) [back to overview]	Counts of Participants With Adverse Event
NCT02159976 (4) [back to overview]	Counts of Participants Whose Drug Compliance is More Than 85%
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (AUC).
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (Vd/F).
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (Vd/F).
NCT02186652 (10) [back to overview]	Drug Concentration in Plasma Samples
NCT02186652 (10) [back to overview]	The CYP2C19 Genotype and Its Association With CYP2C19 Phenotype
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (Cmax).
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (Tmax).
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (CL/F).
NCT02186652 (10) [back to overview]	Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (AUC).
NCT02186652 (10) [back to overview]	PK Sampling
NCT02235311 (4) [back to overview]	Clostridium Difficile Diarrhea
NCT02235311 (4) [back to overview]	Community-Acquired Pneumonia
NCT02235311 (4) [back to overview]	Rate of Rebleed
NCT02235311 (4) [back to overview]	Ulcer Healing
NCT02359435 (1) [back to overview]	Number of Participants in Which H. Pylori Was Eradicated
NCT02432456 (9) [back to overview]	Oral Morphine Equivalent (Narcotic Usage)
NCT02432456 (9) [back to overview]	Respiratory Failure
NCT02432456 (9) [back to overview]	Hallucination
NCT02432456 (9) [back to overview]	Length of Stay
NCT02432456 (9) [back to overview]	Oral Morphine Equivalent (Narcotic Usage)
NCT02432456 (9) [back to overview]	Oral Morphine Equivalent (Narcotic Usage) in Severely Injured
NCT02432456 (9) [back to overview]	Regional Anesthesia Utilization
NCT02432456 (9) [back to overview]	Visual Analog Numeric Pain Score
NCT02432456 (9) [back to overview]	Visual Analog Numeric Pain Score
NCT02467621 (7) [back to overview]	Mortality
NCT02467621 (7) [back to overview]	Number of Serious Adverse Reactions
NCT02467621 (7) [back to overview]	Mortality
NCT02467621 (7) [back to overview]	Number of Participants With Clinically Important GI Bleeding, Pneumonia, Clostridium Difficile Infection or Acute Myocardial Ischemia
NCT02467621 (7) [back to overview]	Number of Participants With Clinically Important GI Bleeding
NCT02467621 (7) [back to overview]	Number of Participants With One or More Infectious Adverse Events
NCT02467621 (7) [back to overview]	Percentage of Days Alive Without Organ Support
NCT02541864 (1) [back to overview]	Number of Participants in Which H. Pylori Was Eradicated
NCT02547038 (1) [back to overview]	Number of Participants in Which H. Pylori Was Eradicated
NCT02551744 (1) [back to overview]	Number of Participants With Ulcer Recurrence
NCT03094416 (14) [back to overview]	Angiotensin Converting Enzyme (ACE)
NCT03094416 (14) [back to overview]	Total Triiodothyronine (TT3)
NCT03094416 (14) [back to overview]	Free Thyroxine (FT4)
NCT03094416 (14) [back to overview]	Ferritin
NCT03094416 (14) [back to overview]	Creatine Phosphokinase (CPK)
NCT03094416 (14) [back to overview]	Thyroid Stimulating Hormone (TSH)
NCT03094416 (14) [back to overview]	Low Density Lipoprotein (LDL)-Cholesterol
NCT03094416 (14) [back to overview]	High Density Lipoprotein (HDL)-Cholesterol
NCT03094416 (14) [back to overview]	Free Triiodothyronine (FT3)
NCT03094416 (14) [back to overview]	Total Thyroxine (TT4)
NCT03094416 (14) [back to overview]	Triglycerides
NCT03094416 (14) [back to overview]	Very Low Density Lipoprotein (VLDL)-Cholesterol
NCT03094416 (14) [back to overview]	Cholesterol, Total
NCT03094416 (14) [back to overview]	Sex Hormone Binding Globulin (SHBG)

Time to Reach Maximum Observed Plasma Concentration (Tmax)

(NCT00141817)
Timeframe: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose

Intervention	hours (Mean)
Pantoprazole 0.6 mg/kg Spheroids	1.45
Pantoprazole 1.2 mg/kg Spheroids	2.71
Pantoprazole 0.6 mg/kg Tablets	2.08
Pantoprazole 1.2 mg/kg Tablets	2.03

Intervention	ng/mL (Mean)
	Hour 2 on Day 7 (n=5, 8, 10, 13)	Hour 4 on Day 7 (n=6, 8, 10, 13)
Pantoprazole 0.6 mg/kg Spheroids	212.30	503.25
Pantoprazole 0.6 mg/kg Tablets	592.32	123.83
Pantoprazole 1.2 mg/kg Spheroids	486.49	207.23
Pantoprazole 1.2 mg/kg Tablets	2337.89	200.78

Intervention	liter per kilogram (L/kg) (Mean)
Pantoprazole 0.6 mg/kg Spheroids	12.22
Pantoprazole 1.2 mg/kg Spheroids	2.89
Pantoprazole 0.6 mg/kg Tablets	0.43
Pantoprazole 1.2 mg/kg Tablets	0.40

Intervention	hours (Mean)
Pantoprazole 0.6 mg/kg Spheroids	5.34
Pantoprazole 1.2 mg/kg Spheroids	1.68
Pantoprazole 0.6 mg/kg Tablets	0.77
Pantoprazole 1.2 mg/kg Tablets	0.70

Intervention	nanogram hour per milliliter (ng*h/mL) (Mean)
Pantoprazole 0.6 mg/kg Spheroids	208.96
Pantoprazole 1.2 mg/kg Spheroids	2273.96
Pantoprazole 0.6 mg/kg Tablets	2448.61
Pantoprazole 1.2 mg/kg Tablets	3190.96

Intervention	ng*h/mL (Mean)
Pantoprazole 0.6 mg/kg Spheroids	293.29
Pantoprazole 1.2 mg/kg Spheroids	2448.08
Pantoprazole 0.6 mg/kg Tablets	2497.13
Pantoprazole 1.2 mg/kg Tablets	3782.49

Intervention	L/hr/kg (Mean)
Low Dose Pantoprazole (0.6 mg/kg)	1.54
High Dose Pantoprazole (1.2 mg/kg)	0.87

Intervention	H*mmol/L (Mean)
	Baseline	Steady state
High Dose Pantoprazole (1.2 mg/kg)	921.0	303.6
Low Dose Pantoprazole (0.6 mg/kg)	259.7	102.3

Intervention	ng*hr/mL (Mean)
Low Dose Pantoprazole (0.6 mg/kg)	1046
High Dose Pantoprazole (1.2 mg/kg)	3602

Intervention	hr (Mean)
Low Dose Pantoprazole (0.6 mg/kg)	1.78
High Dose Pantoprazole (1.2 mg/kg)	1.42

Intervention	ng/mL (Mean)
Low Dose Pantoprazole (0.6 mg/kg)	567
High Dose Pantoprazole (1.2 mg/kg)	1527

Intervention	ng/mL (Mean)
	2 hours	4 hours
High Dose Pantoprazole (1.2 mg/kg)	668	353
Low Dose Pantoprazole (0.6 mg/kg)	289	69

Intervention	patients (Number)
Low Dose Pantoprazole (Approximately 0.3 mg/kg)	0
Medium Dose Pantoprazole (Approximately 0.6 mg/kg)	2
High Dose Pantoprazole (Approximately 1.2 mg/kg)	2

Intervention	units on scale (Mean)
	Vomiting/regurgitation	Choking/gagging	Refusal to eat	Difficulty swallowing	Abdominal/belly pain
High Dose Pantoprazole (Approximately 1.2 mg/kg)	-0.25	-0.47	-0.26	-0.39	-0.28
Low Dose Pantoprazole (Approximately 0.3 mg/kg)	-0.77	-0.43	-0.34	-0.42	-0.42
Medium Dose Pantoprazole (Approximately 0.6 mg/kg)	-0.06	-0.05	-0.16	-0.13	-0.24

Intervention	units on scale (Mean)
	Presence of cold or fever: scale 1=yes 0=no	Cough without cold: scale 1=yes 0=no	Noisy breathing: scale 0(none)-3(most of the time)	Noisy breathing on exhale: scale 1=yes 0=no	Wheezing or whistling sound: scale 1=yes 0=no	Noisy breathing on inhale: scale 1=yes 0=no	Croupy or barky sound: scale 1=yes 0=no
High Dose Pantoprazole (Approximately 1.2 mg/kg)	0.11	-0.24	-0.16	-0.16	-0.02	-0.16	-0.13
Low Dose Pantoprazole (Approximately 0.3 mg/kg)	0.11	-0.38	-0.48	-0.11	-0.15	-0.11	-0.09
Medium Dose Pantoprazole (Approximately 0.6 mg/kg)	0.13	-0.20	-0.19	-0.15	-0.04	-0.16	-0.03

Intervention	units on scale (Mean)
	Week 1 Change from Baseline	Week 2 Change from Baseline	Week 3 Change from Baseline	Week 4 Change from Baseline	Week 5 Change from Baseline	Week 6 Change from Baseline	Week 7 Change from Baseline	Week 8 Change from Baseline	Final Week Change from Baseline
High Dose Pantoprazole (Approximately 1.2 mg/kg)	-0.47	-1.24	-1.38	-1.32	-1.30	-1.42	-1.58	-1.61	-1.66
Low Dose Pantoprazole (Approximately 0.3 mg/kg)	-0.89	-1.11	-1.31	-1.84	-2.05	-1.99	-2.44	-2.34	-2.37
Medium Dose Pantoprazole (Approximately 0.6 mg/kg)	0.02	-0.11	-0.16	-0.20	-0.48	-0.61	-0.58	-0.60	-0.64

Intervention	Percentage of participants (Number)
	Excellent	Good	Satisfactory	Not satisfactory	Missing data
Pantoprazole	67.4	25.0	3.0	0.7	3.9

Intervention	Units on a scale (Mean)
	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
Pantoprazole	6.14	4.62	3.34	2.43	1.94	1.57	1.33

Intervention	percentage of participants (Number)
	Considerably improved	Improved	Unchanged	Missing data
Pantoprazole	56.2	25.7	13.5	4.6

Intervention	percentage of participants (Number)
	None	Mild	Moderate	Severe	Missing data
Pantoprazole / End of Therapy	77.4	20.0	1.1	0.07	1.4
Pantoprazole / Start of Therapy	13.8	38.2	35.9	8.0	4.1

Intervention	participants (Number)
	False negatives (DOB<5) after 3 days of no PPI	False negatives (DOB<5) after 1 day of no PPI
Esomeprazole (Nexium)	0	1
Lansoprazole (Lanton)	1	2
Omeprazole( Losec)	3	4
Pantoprazole (Controloc)	1	2

pantoprazole

Description

Cross-References

Synonyms (129)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (5)

Pathways (2)

Protein Targets (66)

Potency Measurements

Inhibition Measurements

Biological Processes (225)

Molecular Functions (94)

Ceullar Components (63)

Bioassays (146)

Research

Studies (1,382)

Market Indicators

Research Demand Index: 143.13

Study Types

Clinical Trials (186)

Trial Overview

Trial Outcomes

Time to Reach Maximum Observed Plasma Concentration (Tmax)

Plasma Concentrations After Multiple Doses

Terminal-Phase Volume of Distribution (Vz/F)

Plasma Decay Half-Life (t1/2)

Maximum Observed Plasma Concentration (Cmax)

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

Apparent Oral Clearance (CL/F)

Apparent Oral Clearance (CL/F)

Normalized Area of Gastric Hydrogen Ion Activity Over Time

Area Under the Concentration-time Curve (AUC)

Disposition Half-life

Peak Concentration (Cmax)

Time to Peak Concentration (Tmax) Profile

Intragastric pH

Mean Intraesophageal pH

Median Intraesophageal pH

Median Intragastric pH

Normalized Area of Esophageal Hydrogen Ion Activity Over Time

Pantoprazole Plasma Concentration After Multiple-Dose Oral Administration

Percentage of Time Intragastric pH Was >4

Percentage of Time That Intraesophageal pH Was <4

"Number of Patients With Healed Erosive Esophagitis (EE) at End of Study"

Change in Individual Weekly Mean Frequency Score for Each Gastroesophageal Reflux Disease (GERD) Symptom Score From Baseline to Final Week

Change in Individual Weekly Mean Score For Each Respiratory Symptom From Baseline

Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)

Area Under the Concentration-time Curve (AUC)

Half Life

Variance of Oral Bioavailability

Apparent Oral Clearance (Cl/F)

Number of Patients Withdrawn From Study Due to Lack of Efficacy.

Assessment of the Efficacy of Pantoprazole 20 mg/40 mg at Final Visit

Assessment of the Tolerability of Pantoprazole 20 mg/40 mg at Final Visit

Patient's Assessment of Acid Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Patient's Assessment of Lower Abdominal/Digestive Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Patient's Assessment of Nausea During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Patient's Assessment of Upper Abdominal/Stomach Complaints During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Physician's Assessment of Acid Eructation

Physician's Assessment of Heartburn

Physician's Assessment of Painful Swallowing

Patient's Assessment of Sleep Disturbances During the Last 24 Hours (Diaries; ReQuest™ in Practice)

Assessment of Change of Quality of Sleep During Therapy With Pantoprazole

Assessment of the Efficacy of Pantoprazole at Final Visit

Assessment of the Severity of Epigastric Complaints/Epigastric Pain

Assessment of the Severity of Eructation/Acid Eructation

Assessment of the Severity of Heartburn

Assessment of the Severity of Sensation of Fullness/Abdominal Distension

Intervention	units on scale (Mean)
	Length - Baseline (n=12, 45)	Length - Final evaluation (n=12, 45)	Weight - Baseline (n=12, 46)	Weight - Final evaluation (n=12, 46)	Head circumference - Baseline (n=11, 45)	Head circumference - Final evaluation (n=11, 45)
High Dose Pantoprazole	-1.63	-1.04	-1.26	-1.00	-1.06	-0.62
Low Dose Pantoprazole	0.33	0.45	-0.16	-0.05	0.31	0.25

Intervention	patients (Number)
	Potassium (mmol/L)	Carbon dioxide (mmol/L)	Total bilirubin (µmol/L)	CPK (mU/mL)	Gastrin (pg/mL)	Neutrophils (1,000,000,000/L)	Platelet count (1,000,000,000/L)	Urine protein albumin	Urine leukocyte esterase
High Dose Pantoprazole	3	1	1	2	1	0	2	1	3
Low Dose Pantoprazole	0	0	0	0	0	1	0	0	1

Intervention	percentage of subjects (Number)
	TEAEs	SAEs	AEs Leading to Death	AEs Leading to Discontinuation
Cladribine	11.1	0.0	0.0	0.0
Cladribine + Pantoprazole	0.0	0.0	0.0	0.0

Intervention	Percentage of platelet reactivity index (Least Squares Mean)
Omeprazole Concomitant	56.1
Omeprazole Staggered	61.6
Pantoprazole Concomitant	56
Pantoprazole Staggered	61
Clopidogrel Only (Omeprazole Phase)	48.8
Clopidogrel Only (Pantoprazole Phase)	61.0

Intervention	units on a scale (Mean)
	Pain	Symptoms	Activities of Daily Living	Quality of Life	Sports and recreation
MEDIC	17.2	11.4	17.6	17.8	19.3
MEDIC + TKR	34.8	26.4	30.0	38.2	34.5

Intervention	units on a scale (Mean)
	Descriptive index	Visual-analogue scale
MEDIC	0.115	10.2
MEDIC + TKR	0.206	15.0

Intervention	participants (Number)
Pantoprazole 40mg IV Daily and Tube Feed	1
Placebo and Tube Feed.	1

Intervention	percentage of participants (Number)
Pradaxa, 30 Minutes After a Meal (Randomized)	55.9
Pantoprazole 40 mg (Randomized)	67.2

Intervention	percentage of participants (Number)
	Baseline (n= 59 , 58)	GIS 3 (Week 1, n= 59 , 58)	GIS 4 (Week 2, n= 59 , 58)	GIS 5 (Week 3, n= 59 , 58)	GIS 6 (Week 4, n= 59 , 58)	GIS 7 (Week 5, n= 14 , 15)	GIS 8 (Week 6, n= 14 , 15)	GIS 9 (Week 7, n= 14 , 15)	GIS 10 (Week 8, n= 14 , 15)
Pantoprazole 40 mg (Randomized)	0.0	51.7	55.2	60.3	67.2	40.0	40.0	33.3	33.3
Pradaxa, 30 Minutes After a Meal (Randomized)	0.0	39.0	45.8	55.9	55.9	28.6	42.9	42.9	42.9

Intervention	percentage of participants (Number)
Pradaxa, 30 Minutes After a Meal (Randomized)	11.9
Pantoprazole 40 mg (Randomized)	19.0